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TIIVISTELMÄ	  
Flavivirukset (suku Flavivirus, heimo Flaviviridae) ovat zoonoottisia viruksia, joista 
suurin osa tarttuu niveljalkaisten, hyttysten ja puutiaisten, välityksellä. 
Maailmanlaajuisesti flavivirusten aiheuttamia lievempiä ihottuma- ja kuumetauteja, 
sekä vakavampia keskushermostoinfektioita todetaan vuosittain satoja miljoonia. 
Denguekuume, Japanin aivotulehdus eli enkefaliitti, Länsi-Niilin kuume ja keltakuume 
ovat esimerkkejä flavivirusinfektioista. Hyttysvälitteiset flavivirukset säilyvät luonnossa 
kädellisten ja hyttysten välillä. Ne voivat myös vaihtaa urbaaniin kiertokulkuun 
ihmisten ja hyttysten välille, luoden näin mahdollisuuden epidemioille. Viime vuosina 
Zikavirus (ZIKV) on aiheuttanut laajan epidemian Etelä- ja Väli-Amerikassa. Tätä 
epidemiaa karakterisoivat erityisesti sikiöillä ja vastasyntyneillä esiintyneet infektiot 
aiheuttaen eriasteisia keskushermoston kehityshäiriöitä, kuten mikrokefaliaa. 
Puutiaisten välittämistä flaviviruksista puutiaisaivokuumevirus (TBEV) on 
kotoperäinen useassa Euroopan maassa. Suomessa sitä esiintyy rannikolla ja itäisessä 
Suomessa, pohjoisessa aina Simoon asti. Viime vuosina tautitapausten määrä on ollut 
kasvussa, ja myös kuolemaan johtaneita tapauksia on raportoitu. Tässä 
väitöskirjatutkimuksessa keskitytään näiden kahden keskushermostoinfektioita 
aiheuttavien flavivirusten, ZIKV ja TBEV, karakterisointiin. 
Väitöskirjatyössä kuvailemme raskaana olevan naisen zikavirusinfektion ja sen 
aiheuttaman vakavan seurauksen sikiölle. Zikavirusinfektion todettiin aiheuttavan 
potilaalla poikkeuksellisen pitkittyneen viruserityksen. Eristimme zikaviruksen sikiön 
aivokudoksesta, ja osoitimme näin osaltaan zikaviruksen ja sikiön aivovaurion 
yhteyden. Uuden sukupolven sekvensointitekniikkaa hyödyntäen selvitimme viruksen 
perimän. Zikavirusinfektion hoitoon ei ole vielä tehokasta viruslääkettä. Testasimme 
valikoitujen, jo tunnettujen antiviraalisina yhdisteinä vaikuttavien lääkkeiden tehoa 
zikavirusinfektioon soluviljelymallissa eristetyn viruksen avulla. Löysimme kolme 
solun omiin toimintoihin vaikuttavaa lääkeainetta, obatoclax, SaliPhe ja gemsitabiini, 
jotka estivät tehokkaasti zikaviruksen aiheuttaman solukuoleman. Nämä yhdisteet 
vaikuttivat viruksen ja isäntäsolun vuorovaikutuksiin viruksen elinkierron eri vaiheissa. 
Tutkimuksen kohteena olevaa vakavan tautimuodon aiheuttamaa zikaviruskantaa 
verrattiin soluviljelymallissa muihin lievempiä epidemioita aiheuttaneisiin 
zikaviruskantoihin. Tutkimuksessa osoitettiin aivokudoksesta eristetyn viruksen 
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lisääntyvän tehokkaasti kohdusta, napasuonista, munuaisista ja aivoista peräisin olevissa 
solulinjoissa.  
Kotkan saaristossa on viimeisen vuosikymmenen aikana todettu uusi 
puutiaisaivokuumefokus. Erityisen merkittävän siitä tekee siellä esiintyneet vakavat 
TBEV-infektiot. Vuonna 2015 Kuutsalon saaressa esiintyi useita 
puutiaisaivokuumetapauksia, joista kaksi johtivat kuolemaan. Eristimme viruksen toisen 
tapauksen aivokudoksesta soluviljelmässä, ja virus osoittautui TBE-viruksen 
siperialaiseksi alatyypiksi. Aiemmassa tutkimuksessa Kotkan saaristosta on löydetty 
saman alatyypin TBE-virusta puutiaisita. Toinen tapauksista osoittautui täten hieman 
yllättäen viruksen eurooppalaisen alatyypin aiheuttamaksi. Löysimme saaristosta myös 
tätä alatyyppiä puutiaisesta, mikä osoittaa, että kaksi viruksen alatyyppiä esiintyvät 
poikkeuksellisesti samassa fokuksessa. 
  
11  
ABSTRACT	  
Flavivirus is a genus that consists of small RNA viruses transmitted by arthropod 
vectors, mosquitos and ticks. Flaviviruses cause human diseases of global concern, such 
as dengue fever, Yellow fever, West Nile disease and Japanese encephalitis, with 
hundreds of millions of infections every year. Zika virus (ZIKV), a mosquito-borne 
flavivirus, recently caused a major epidemic with severe and unexpected consequences. 
Circulating in sylvatic cycles for decades and traditionally causing only mild self-
limiting disease, ZIKV quickly spread through the Americas between 2015 and 2016, 
leading to an unforeseen epidemic that affected hundreds of thousands of people. 
Following this outbreak of acute ZIKV infections, the number of microcephaly cases 
reported in neonates accumulated; a causal relationship was suspected and the World 
Health Organization declared a Public Health Emergency of International Concern in 
February 2016.  
We were able to provide a key piece of evidence in proving the causal relationship 
between ZIKV infection and microcephaly. We described a case of prolonged maternal 
viremia from an expectant mother infected with ZIKV at the 11th week of gestation, 
which led to brain damage in the fetus. Subsequently, we isolated the virus FB-FWUH-
2016 from the brain tissue of the fetus in human neuroblastoma cells.  
There is no specific anti-viral treatment for ZIKV infections nor is there a fully effective 
vaccine. Thus, we screened several anti-cancer compounds known to possess anti-viral 
activities to determine their anti-Zika virus effectivity. We found that gemcitabine, 
saliphenylhalamide and obatoclax, the latter of which is a novel compound, inhibited 
ZIKV replication and virus production in retinal pigment epithelial cells. Furthermore, 
we found that the compounds differentially affect the metabolism of infected cells. 
These data provide novel information for anti-virus drug development, as these 
compounds affect the functions of infected cells instead of the virus itself. We further 
characterized the new epidemic virus isolate and conducted a study on cell tropism. In 
this study, we compared four ZIKV isolates, three of which were from the epidemic 
Asian lineage and the other was a prototypic virus of the African lineage. We found 
differences in cell susceptibility that favored the new strain and a closely related French 
Polynesian strain, particularly in cell lines originating from the placenta, umbilical 
veins, kidney and brain.  
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Tick-borne encephalitis virus (TBEV), another flavivirus that affects the central nervous 
system, is endemic in many parts of Europe and in the Northern parts of Asia. Three 
subtypes of the virus, namely, the European, Siberian and Far Eastern subtypes, can 
cause encephalitis with different degrees of severity. The European subtype is most 
prominent in most of Europe, but the Siberian subtype is also found in the Baltic 
countries and Finland. Fatalities are rare, which made the Kotka Archipelago in Finland 
a new focus after the report of two fatal TBE cases in 2015 from the same island in the 
archipelago along with two other infected individuals. We isolated the virus from the 
brain of one of the deceased patients in human neuroblastoma cells and obtained 
sequence data on both fatal cases. Surprisingly, the viruses were the Siberian and 
European subtypes. During this and previous studies, we also found both viruses in 
ticks from the archipelago, which shows that the subtypes coexist in the same focus. 
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REVIEW	  OF	  THE	  LITERATURE	  
Introduction	  
Viruses in the genus Flavivirus comprise a group of emerging viruses of global, 
regional and endemic concern that vary greatly in their pathogenic potential. The 
mechanisms by which these viruses cause human disease differ, and flaviviruses are 
associated with a wide spectrum of human disease, from dengue and yellow fever mild 
febrile disease to hemorrhagic manifestations and from tick-borne encephalitis to severe 
congenital infections and Guillain-Barré syndrome caused by Zika virus.  
Flaviviruses are small positive-sense RNA-viruses in the family Flaviviridae. The 
prototype yellow fever virus (lat. flavus = yellow) gives the family its name and is the 
causative agent of a severe febrile disease in the tropics. The Flavivirus genus consists 
of over 50 viruses, most of which cause emerging and re-emerging human diseases 
through arthropod vectors (1,2).  
Many members of the genus Flavivirus are neuropathogenic, i.e., they cause disease in 
the central nervous system (CNS). Recently, two such emerging viruses with severe and 
fatal consequences were brought to our attention. In this thesis work, we focus on these 
neuropathogenic flaviviruses with different epidemiological and ecological 
characteristics as well as disease associations: mosquito-borne Zika virus (ZIKV) and 
tick-borne encephalitis virus (TBEV).  
Tick-borne encephalitis was first described as “meningitis serosa epidemica” in Austria 
in 1931 by H. Schneider (3). The causative agent, TBEV, was later isolated in Russia in 
1937 after a similarly described illness in the Far East in 1934 (4). In the 1940s, TBE 
was called Kumlinge disease in Finland, and later in 1948, the first TBE virus was 
isolated during an epidemic in Czechoslovakia (5,6). During the past few years, ZIKV 
has caused an alarming epidemic in the Pacific and the Americas that is associated with 
microcephaly and Guillain-Barré syndrome. ZIKV was first discovered in the Zika 
forest in Uganda in 1947 during a study on yellow fever virus (7). It was isolated from a 
rhesus monkey caged in the Zika Forest, and a year later, ZIKV was isolated also from 
Aedes africanus mosquitos trapped in the same forest. While TBEV has caused regional 
infections in endemic areas since the days of its discovery, ZIKV remained silent for 
decades. Until 2007, Zika virus caused only sporadic human cases, with altogether 
fewer than 20 cases reported (8). 
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Taxonomical	  classification	  
The family Flaviviridae is divided into four genera: Flavivirus, Hepacivirus, Pegivirus 
and Pestivirus. The viruses are antigenically distinct between the genera, but cross-
reactivity within each genus is common. Members in all four genera have enveloped 
spherical virions 40-60 nm in diameter with a non-segmented single-stranded 9-13 kb 
RNA genome packed inside a capsid. The four genera share similar genome 
organization in regions coding for serine protease, helicase and RNA-dependent RNA 
polymerase (9). Viruses in the genus Flavivirus differ in their antigenic, ecological and 
epidemiological characteristics. Most flaviviruses infect vertebrates and invertebrates, a 
feature not shared by members in the Pestivirus, Hepacivirus and Pegivirus genera (10). 
In addition, only flaviviruses have a type 1 cap structure at the 5’-end of their genomes 
and produce a subgenomic non-coding RNA from the 3’-untranslated region (UTR) 
(11). 
The genus Flavivirus (hereafter referred to as flaviviruses; Figure 1) forms a 
monophyletic lineage that can be divided into three main clades based on their vector 
association: a mosquito-borne clade (e.g., Yellow fever virus, dengue viruses and 
Japanese encephalitis viruses), a tick-borne clade (e.g., Tick-borne encephalitis virus, 
Louping ill virus and Langat virus), and a no-known-vector or mosquito only clade of 
insect-specific flaviviruses (ISFVs) (e.g., Entebbe bat virus, Dakar bat virus and San 
Perlita virus) (10). Approximately 50% of known flaviviruses are mosquito-borne, 28% 
are tick-borne and the remaining 22% are agents with no known arthropod vector or 
ISFVs (10).  
Currently, the tick-borne clade includes twelve recognized species that are divided into 
two groups, the mammalian tick-borne virus group and the seabird tick-borne virus 
group. The evolutionary characteristics of these groups are largely determined by their 
mode of transmission, which affects their antigenic relationships, genetic diversity and 
geographical distribution (12,13). The mammalian tick-borne virus group consists of six 
human and animal pathogens: tick-borne encephalitis virus (TBEV), Louping ill virus 
(LIV), Omsk hemorrhagic fever virus (OHFV), Langat virus (LGTV), Kyasanur Forest 
disease virus (KFDV) and Powassan virus (POWV). Three other viruses (Royal Farm 
virus (RFV), Karshi virus (KSIV) and Gadgets Gully virus (GGYV)) that are not known 
to be human pathogens are currently included in this group (10,12). The TBEV species 
has three main subtypes: European (Eur; previously Central European Encephalitis 
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CEE), Siberian (Sib; previously West Siberian encephalitis) and Far Eastern (FE; 
previously Russian spring-summer encephalitis) (14).  
ZIKV belongs to the Spondweni serocomplex together with Spondweni Virus. ZIKV 
has evolved into three genotypes: West African (Nigerian cluster), East African 
(prototype MR766 cluster), and Asian. It has been suggested that the virus originated in 
East Africa and then spread approximately 100 years ago to West Africa and Asia (15). 
ZIKV is antigenically closely related to dengue viruses (DENV). DENV and ZIKV 
circulate in the same geographical areas and are transmitted by Aedes mosquitoes. There 
are four serotypes of dengue (DENV 1-4), and they differ from each other by 30-35% in 
the amino acid sequence of envelope protein E. In turn, the DENV serocomplex differs 
by 41-46% from ZIKV (16).  
 
 
Figure 1. Taxonomical classification of the Flavivirus genus. Phylogenetic tree based on 
representatives of all flavivirus species for which a complete coding sequence is available. For clarity, 
bootstrap values are shown only for the major clusters. Courtesy of Dr. Teemu Smura. 
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Flavivirus	  structure	  and	  replication	  
Flavivirus particles are approximately 50 nm in diameter. The virion consists of three 
structural proteins (capsid (C), precursor of membrane (prM) and envelope (E)), the 
positive-sense RNA genome and a lipid membrane. Seven nonstructural proteins (NS1, 
NS2A, NS2B, NS3, NS4A, NS4B and NS5) are expressed in infected cells (17). Unlike 
many other enveloped viruses, the envelope protein E lies parallel on the virion surface 
and is organized in a head-to-tail orientation, forming an icosahedral structure with the 
other envelope protein M (Figure 4). E protein is the major antigenic determinant of the 
virus, and it mediates membrane fusion during virus entry. The membrane protein M is 
a small fragment of the precursor protein prM, and it is formed after virion maturation 
by furin protease cleavage under low pH conditions prior to exocytosis. The RNA 
genome is enclosed by the third structural protein capsid (C) (17).  
	  
Genome	  structure	  
The flavivirus genome is a single positive-stranded RNA of approximately 11 kilobases 
(Figure 2). It is capped at the 5’-end by a type 1 5’ cap (m7GpppAmpN2). The flavivirus 
genome is not usually polyadenylated at the 3’ end, unlike cellular mRNA, although 
some TBEV genomes have been shown to contain a poly-A tail (18). The genome has 
one open reading frame flanked by 5’ and 3’ untranslated regions (UTRs) that are 
approximately 100 nucleotides and 400-700 nucleotides long, respectively (Figure 2).  
 
Figure 2. Flavivirus genome structure and organization. 
The 5’ and 3’UTRs are not well conserved among flaviviruses, but they contain 
common secondary structures that play a role in translation and replication of the viral 
genome (19). Several host transcription factors and regulatory and RNA-binding 
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proteins, such as La, p100, FBP1 and Mov34, have been reported to bind to flaviviral 3’ 
UTR (20-25). Some TBEV strains that are cell-line adapted or were isolated from 
humans have deletions or polyA insertions in the 3’UTR. These mutations have been 
reported to increase the virulence of the viruses (26-28). 
 
Translation	  and	  polyprotein	  processing	  
As for all positive-strand RNA viruses, the flavivirus genome serves as a messenger 
RNA for translation. The single open reading frame is translated into one long 
polyprotein of approximately 3500 amino acids, which is cleaved co- and post-
translationally into at least 10 proteins (Figure 3). The structural proteins are encoded 
by the amino-terminal part of the genome, followed by the nonstructural proteins. The 
one long polyprotein translocates into the endoplasmic reticulum (ER), and individual 
proteins are released either on the luminal side (prM, E, NSI and NS4B) or the 
cytoplasmic side (NS2A, NS2B, NS3, NS4A and NS5) with transmembrane anchors 
(Figure 3). The protein cleavages are performed by several proteases, most importantly 
by the host signal peptidase and viral serine protease (NS2B/NS3). The host signal 
peptidase is known to cleave between the structural glycoproteins, while the cleavages 
between the nonstructural proteins are made mainly by the viral protease (17). The 
processing of the NS4A/NS4B junction requires both cellular and viral proteases (29) 
(Figure 3). 
 
 
Figure 3. Flavivirus polyprotein processing and ER membrane topology. Modified from ref. (30) 
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Viral	  proteins	  
Capsid protein 
Capsid protein (C) is a highly basic protein of relatively small size (11 kDa)  (31)The 
nucleocapsid consists of C homodimers that interact with the positively charged basic 
residues in both the N- and C-termini with the negatively charged viral genome, 
enclosing an electron dense core of ca. 30 nm (32,33). Capsid protein plays a role in 
infectious virus assembly via interactions with viral genome (34). As virion maturation 
occurs, the viral serine protease releases the C protein from its anchor at the C-terminus 
(anchored C; anchC), which serves as a signal peptide for prM to translocate into the 
ER (35,36). 
Membrane protein 
The glycoprotein precursor of the membrane protein M (prM) is an approximately 26 
kDa type I integral membrane protein that contains 1-3 glycosylation sites (37,38). The 
N-terminal ‘pr’ segment of the protein is hydrophilic, and it is released into the 
extracellular milieu along with mature virus particles. prM and E form a 1:1 complex, 
preventing premature activation of the virion in conditions of low pH in the trans-Golgi 
network (TGN) (37,39). Prior to virion budding, mature virions are produced by furin 
cleavage of prM directly after the consensus sequence Arg-X-Arg/Lys-Arg into ‘pr’ and 
M (40). The prM protein acts as a chaperone-like protein for E, enabling it to fold 
correctly into its native conformation (37). 
Envelope protein 
The envelope protein (E) is the viral hemagglutinin and major antigenic determinant, 
and it is involved in receptor binding and membrane fusion. E is also a type I membrane 
protein approximately 53 kDa in size that typically contains 1 to 2 glycosylation sites  
(37,41). The number of glycosylation sites is not conserved among flaviviruses, and it 
has been suggested that glycosylation patterns modulate receptor binding (42). The E 
monomer consists of three structural domains (I, II and III), the structures of which have 
been determined to a resolution of 2.0 Å (43,44) (Figure 4). The fusion peptide is highly 
conserved among flaviviruses and is located at the tip of domain II (Figure 4). The 
putative receptor-binding sites reside in domain III (37,45). The flavivirus E protein 
forms a distinct class of fusion proteins (class II) with alphavirus E1 that is defined by 
the presence of the distinct three-domain structure with an internal fusion peptide. After 
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furin cleavage, the E protein acquires its flat conformation on the mature virion surface 
(Figure 4). 
 
 
Figure 4. Flavivirus virion structure. (A) Immature and mature particles differ in their orientation of 
the E protein. (B) Cryo-EM visualization of the virion. E protein dimers form a herringbone-like 
structure. The 2-, 3- and 5-fold symmetry axes are shown. (C, D) Ribbon diagrams of the crystal structure 
of the TBEV E protein dimer. Domains I, II and III are in red, yellow and blue, respectively, and the 
fusion loop is in green. Reproduced with permission from Heinz FX and Stiasny K, J Clin Virol 2012  
(46). 
 
NS1 
NS1 is a multifunctional glycoprotein approximately 46 kDa in size. NS1 translocates 
into the lumen of the ER through a signal sequence at the C-terminus of E, and it is 
cleaved from the envelope protein by a host signal peptidase. Downstream cleavage 
from the NS2A protein is catalyzed by an unknown ER-resident host protease shortly 
after synthesis (47), at which time NS1 forms homodimers that associate with 
membranes (32). NS1 exists as a monomer, dimer and a hexamer. NS1 functions in 
genome replication and is involved in replication complex (RC) formation together with 
NS4A and NS4B. Dimeric NS1 forms soluble hexamers in the Golgi network, which 
are released outside of the infected cell (47). NS1 also antagonizes innate immune 
responses of the host (48,49).  
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NS1 is highly conserved among flaviviruses: it shares 90% amino acid homology with 
different TBEV strains and as high as 44% homology with different flaviviruses (50). In 
natural flavivirus infections, the extracellular form of NS1 elicits a strong immune 
response in the host. Immunization of mice with the DENV and TBEV NS1 proteins, 
and of monkeys with the YFV NS1 protein, has been demonstrated to protect them from 
lethal challenge (51,52). 
A ribosomal frameshift in the translation of the polyprotein has been shown to occur in 
NS1, producing another form of the protein, NS1’. This frameshift has been shown to 
play a role in virus neuroinvasiveness (53). 
NS2A and NS2B 
NS2A is a small (22 kDa) hydrophobic protein. It functions in virus replication and 
assembly and has been shown to antagonize type I interferon (IFN) responses (54). The 
C-terminal cleavage of NS2A from NS2B occurs via the viral serine protease 
NS3/NS2B. NS2B is a membrane-associated protein approximately 14 kDa in size. Its 
conserved hydrophilic core region functions as a key cofactor for the viral serine 
protease complex it forms with NS3 (55,56). NS2B antagonizes innate immune 
responses, and, together with NS3, it has been shown to play a role in TBEV 
neuroinvasiveness (57,58). 
NS3 
NS3 is a large 70-kDa multifunctional cytoplasmic protein associated with membranes 
via its interaction with NS2B. The catalytic triad (His-Asp-Ser) in the active site of 
mammalian serine proteases is critical for their protease function, and it has been found 
to be conserved in the NS3 proteins of all flaviviruses (59). NS3/2B catalyzes the 
autocleavage (cis) of NS2A/NS2B and NS2B/NS3 and the trans cleavage of NS3/NS4A 
and NS4B/NS5 (60). The C-terminal part of NS3 is involved in viral RNA replication 
as an RNA helicase, nucleotide 5’-triphosphatase (NTPase) and RNA 5’-triphosphatase 
(RTPase), and it associates with NS5 to form the RC (61). 
NS4A and NS4B 
NS4A and NS4B are small integral membrane proteins 16 and 27 kDa in size, 
respectively. NS4A and NS4B are connected via a conserved signal peptide called 2K. 
2K is cleaved by the viral serine protease to form mature NS4A, which is subsequently 
cleaved from NS4B by a host signal peptidase. NS4A and NS4B function primarily in 
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replication as they are essential components of the RC (29). NS4B has been shown to 
interfere in the RNA binding of helicase by binding to NS3, thus removing the single-
stranded RNA from NS3 (62,63).  
NS5 
NS5 is a large 104-kDa protein that contains two distinct domains: the N-terminal S-
adenosyl-methionine (SAM) transferase domain and the C-terminal RNA-dependent 
RNA polymerase domain (RdRp) (64). The methyltransferase activity is associated with 
the 5'-cap formation of newly synthesized viral RNA. The interdomain region of NS5 is 
involved in RC formation and also contains a functional nuclear localization signal 
(NLS), which binds to the nuclear import receptors importin-b1 and importin-a/b (65). 
The NTPase activity of NS3 is stimulated by binding of the RdRp domain of NS5, 
exposing the active site of NS3 to the substrate (66) 
 
Flavivirus	  life	  cycle	  
Flaviviruses enter cells through receptor-mediated endocytosis. Several cell surface 
proteins have been identified as putative receptors for flaviviruses. Among others, 
heparan sulfate proteoglycans, dendritic cell-specific ICAM-3 grabbing non-integrin 
(DC-SIGN) and AXL have been identified as candidate flavivirus receptors, but their 
precise roles are not clear (42,67,68). Upon attachment, virions are internalized into 
clathrin-coated pits and vesicles (Figure 5). Virions are stable in slightly basic 
conditions (~pH 8), and upon attachment, the acidification (pH ~6.6) of the endosome 
causes the E homodimers to monomerize and rearrange into homotrimers, releasing the 
nucleocapsid into the cytoplasm (40,43,46). After nucleocapsid uncoating, the genome 
is translated into one long polyprotein at the ER membrane. Genome replication occurs 
at membrane-associated RCs localized to the perinuclear region (65).  
Flavivirus assembly occurs in the ER, where the proteins and viral RNA are combined 
into immature virus particles (Figure 5). Virions gain their lipid envelope by budding 
into the ER. pH and protease-dependent maturation occurs in the TGN, prM is cleaved 
by the host protease furin, and the E protein undergoes major reorganization (40). prM 
and mature virions are released from the host cell by exocytosis at the plasma 
membrane (17). In addition to mature virus particles, immature or partially immature 
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particles that are infectious through antibody-dependent enhancement (ADE), are 
released (69). 
Virus-like particles 
Flavivirus-infected cells have been shown to release particles containing only the 
envelope proteins E and M and the lipid envelope. These virus-like particles (VLPs) are 
noninfectious and smaller in size (approximately 30 nm in diameter) than the infectious 
virions, and they possess hemagglutination activity (77). The maturation and assembly 
of VLPs seem to be very similar to those of the virus: VLPs undergo low-pH induced 
rearrangement of envelope proteins and are able to undergo membrane fusion.  
 
 
Figure 5. Flavivirus life cycle. Reproduced with permission from Mukhopadhyay et al. Nat. Rev. 
Microbiol, 2005 (17). 
 
Immune	  recognition	  of	  flavivirus	  infection	  
While immune reactions are important for restricting (neuropathogenic) virus growth 
and spread to the brain, these reactions may also cause neurological damage. Immune 
defense against different pathogens is mediated by early innate immune reactions as 
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well as the later responses of adaptive immunity. Innate immunity serves as the first-
line of response against microbes and includes their possible elimination, effector 
mechanisms of adaptive immunity, and the stimulation of adaptive immune responses. 
In host cells, interferons (IFNs) and other cytokines are produced in response to viral 
infection. A variety of cells, such as macrophages, lymphocytes and monocytes, as well 
as fibroblasts, endothelial and stromal cells, are able to produce cytokines upon 
infection. 
Cells recognize the products of infection, e.g., viral double-stranded RNA, through 
pathogen recognition receptor proteins (PRRs). Several families of PRRs exist, but 
Toll-like receptor (TLR) family proteins in the endosomes and the cytoplasmic RNA 
helicases (RLR), RIG-I and MDA5, are the most important in flavivirus infection (70). 
These PRRs recognize pathogen-associated molecular patterns (PAMPs) and induce 
signal pathways that result in the production of type I interferons (IFNa and -b) and 
inflammatory cytokines. In particular, IFNa and -b are the key cytokines that mediate 
the induction of both the innate immune response and the following development of 
adaptive immunity to viruses (71).  
The exact role of TLR-3 in flavivirus infection is not completely understood, but it has 
been shown to restrict DENV and WNV replication (72,73). Both RLRs, RIG-I and 
MDA5, are DExD/H box RNA helicases that function independently of TLRs in RNA-
virus infection. RIG-I and MDA5 contain tandem caspase activation and recruitment 
domains (CARDs) that activate downstream signaling (74). RIG-I interacts with the 5’-
phosphorylated ends as MDA5 binds internally (75). RIG-I interacts downstream with 
mitochondrial bound MAVS (also known as Cardif, IPS-1 or VISA) (76), which is 
important for RIG-I-dependent signaling (77). The interaction of RIG-I and MAVS 
activates the downstream kinases IKKe and TBK-1, which in turn phosphorylate the 
IRF-3 and IRF-7 transcription factors. Interferons affect neighboring cells by inducing 
the JAK/STAT pathway and the subsequent production of several interferon-stimulated 
genes (ISGs) that further function in limiting the infection. MxA is an interferon-
inducible GTPase that is known to have broad antiviral activity against numerous 
viruses. 
Flaviviruses have developed strategies to interfere with innate immune responses. It has 
been shown that ZIKV fails to induce an ISG response in many cell types. Several 
proteins have been identified to inhibit IFN induction and signaling. DENV NS2B/NS3 
inhibits IFN induction by cleaving the MITA/STING signaling protein (58,78). The 
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NS5 protein of ZIKV, DENV and TBEV has been shown to interfere with IFN 
signaling by interacting with STAT proteins (79-81). ZIKV NS5 function in STAT2 
cleavage seems to be restricted by host species, as it is functional in humans and non-
human primates but not in mice. Interferon antagonism has also been described for 
NS2A and NS4B of DENV and WNV (82,83). In addition to specific protein functions, 
TBEV has been shown to delay IFN production by hiding dsRNA in ER-derived 
membrane structures (84).  
The complement system is also considered to be part of innate immunity. The 
complement system comprises several proteins circulating in blood, and it is activated 
upon recognition of an invading pathogen. Classical, lectin or alternative pathways are 
activated, depending on the stimuli. Studies on DENV and WNV have revealed 
interactions with the NS1 protein and components of the complement system (factor H 
and C4) to evade the proteolytic activation of the complement system (48,85). 
Cellular macroautophagy is a process that results in the lysosomal degradation of 
cellular organelles and proteins. Autophagy regulates cellular homeostasis and functions 
as a part of the innate immune response to infections. Autophagy has also been shown 
to exhibit pro-viral functions, and several viruses have evolved strategies to evade or 
subvert these lysosomal processes to their advantage during different stages of the 
replication cycle (86). Flaviviruses have been, although somewhat controversially, 
reported to usurp autophagy at some stage of the life cycle (87-89). In particular, ZIKV 
NS4A and NS4B proteins have been shown to induce autophagy by suppressing the 
Akt-mTOR signaling pathway (86). 
 
Epidemiology	  
Flaviviruses are distributed worldwide, but individual species are restricted to endemic 
or epidemic areas. Yellow fever virus is found in tropical and subtropical regions in 
Africa and South America, Japanese encephalitis virus in Southeast Asia and dengue 
throughout the tropics and subtropics globally. More than half of flaviviruses are 
associated with human disease. These diseases may be associated with the central 
nervous system (e.g., WNV, JEV, TBEV and ZIKV), hemorrhagic fever (e.g., DENV 
and YFV) or more generalized infections with fever, arthralgia and rash (DENV and 
ZIKV). Many are also economically important diseases in domestic and wild animals. 
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Mosquito-borne neuropathogenic flaviviruses have caused epidemics around the world. 
A major epidemic of West Nile virus occurred in North America in the late 20th century, 
when the virus was first detected in New York in 1999. WNV caused nearly 6000 cases 
of meningitis or encephalitis during 2002-2003, causing over 300 deaths (90). WNV has 
also emerged in several countries in Europe (91). In Asia, Japanese encephalitis virus 
causes 10 000 deaths annually (92). Other members in the JE-serogroup that cause 
encephalitis include St Louis encephalitis virus in the USA and Murray Valley 
encephalitis virus in Australia (90). In many cases, humans are a dead-end-host for the 
virus, but some mosquito-borne flaviviruses are able to shift the transmission cycle to a 
human-mosquito-human cycle, enabling their effective spread and increasing their 
epidemic potential. Tick-borne encephalitis virus is endemic in Europe and Asia, and it 
is considered an important pathogen that affects the CNS. The impact of Zika virus and 
its newly identified CNS disease associations are on the verge of being characterized 
(Table 1).  
 
Table 1. Neuropathogenic flaviviruses. Table of globally important neuropathogenic flaviviruses  
(90,93-96). CNS, central nervous system; Eur, European subtype; Sib, Siberian subtype; FE, Far Eastern subtype; 
GBS, Guillain-Barré syndrome. 
	  
 	  
VIRUS GEOGRAPHIC 
DISTRIBUTION 
PRINCIPAL 
VECTOR 
SPECIES 
CLINICAL TO 
SUBCLINICAL 
RATIO 
TYPE OF HUMAN CNS 
DISEASE 
(PATIENTS PRESENTING 
SYMPTOMS) 
CASE 
FATALITY 
RATE 
JAPANESE 
ENCEPHALITIS 
Asia 
Culex 
tritaeniorhynchus 
1/25 (adults), 
1/250-1000 
(children) 
Encephalitis (60-75%) 
Meningitis (5-10%) 
20-30% 
MURRAY 
VALLEY 
ENCEPHALITIS 
Australia 
New Guinea 
Culex annulirostris 1/700 - 1/1200 
Encephalitis (50%) 
Meningitis (50%) 
15-30% 
ST LOUIS 
ENCEPHALITIS 
South and 
Central America 
Culex spp 1/250 
Encephalitis (58-85%) 
Meningitis (5-40%) 
3-30% 
TICK-BORNE 
ENCEPHALITIS 
Europe 
Asia 
Ixodes spp 
1/3-5 
(10-30% develop 
CNS disease) 
Meningitis (50%) 
Meningoencephalitis (40%) 
Meningoencephalomyelitis 
(10%) 
<2% Eur 
2-4% Sib 
20-40% FE 
WEST NILE Worldwide Culex spp 
1/5 (fever), 
1/140-320 (CNS 
disease) 
Encephalitis (60%) 
Meningitis (15-40%) 
4-16% 
ZIKA 
Africa 
Asia 
Americas 
Oceania 
Aedes spp 2/10 
Microcephaly (0.88-
13.2/1000), GBS (0.24/1000), 
Meningoencephalitis 
Data not 
established 
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Tick-­‐borne	  encephalitis	  
 
TBEV is considered the most important arthropod-borne virus in Europe. It is endemic 
in most European countries, Russia, China and Japan. Close to 3000 cases occur in 
Europe annually, and up to 10 000 cases have been reported in Russia. In endemic 
regions, the majority of TBEV infections are subclinical, and fewer than half of the 
patients report a tick bite (14). TBEV infections usually occur under altitudes of 750 m, 
but in recent years, the virus has expanded to new areas up to and above 1500 m in 
altitude (97,98). Human infections follow the seasonal peaks of I. ricinus and I. 
persulcatus feeding activity in Europe and of I. persulcatus in Asia. In Central Europe, 
ticks are active in two peaks: from May to June and from September to October, and the 
peaks in human disease follow 3-4 weeks later. In Fennoscandia, only one peak is 
recorded in the late summer/autumn, except in areas with I. persulcatus, where a peak is 
observed mainly in the early summer (O. Vapalahti, personal communication).  
 
 
Figure 1. TBE incidence in Europe in 2016  (99). 
The highest incidence of tick-borne encephalitis (TBE) is in Baltic countries (Latvia 
14.6/100 000, Lithuania 18.5/100 000), Slovenia (18.6/100 000), Czech Republic 
(10/100 000) and western Siberia (40-80/100 000)  (100-102). Before the 1980s and the 
mass vaccination campaign, the highest morbidity rates of TBE in Europe were 
recorded in Austria. To date, vaccination coverage includes approximately 85% of 
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Austrian citizens, and the cases of TBE have decreased from 300-700/year to 70. The 
incidence among unvaccinated individuals is approximately 5/100 000  (103,104). 
There is an increasing trend of TBE cases in Europe, and during recent years, the 
prevalence has expanded to higher latitudes in Finland, Sweden and Russia  (105-107). 
The number of TBE cases has risen in Czech Republic from approximately 350 per year 
in the beginning of the 1980s to approximately 500-600 per year in 2010 (99).  
In Finland, 20-40 cases of TBE were reported up to 2009, but during the last decade, the 
number has increased to a record of 67 in 2015, followed by 61 reported cases in 2016 
(Figure 6). The endemic foci are situated mainly on the Åland Islands, along the 
coastlines, and in the Lake District, but new foci appear continuously. The endemic 
areas have spread to Kokkola, Lappeenranta, Simo, Isosaari Island in Helsinki and 
Kotka; furthermore, the Siberian subtype has been detected in Kokkola and Kotka. A 
vaccination campaign was started in 2006 in Åland, where the TBE incidence has been 
the highest in Finland. Vaccination coverage has reached 70%, which has led to a 
decrease in cases from 70 to 30/100 000 in the archipelago, and mainland cases 
predominate at present (108). In 2017, TBEV was included in the National vaccination 
program in Simo and Parainen, municipalities that are high-risk TBE areas, i.e., areas in 
which the TBE incidence exceeds 5 cases/100 000 per year (109). 
 
 
Figure 6. The number of reported TBE cases in Finland 1995-2016 (110). 
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Zika	  virus	  disease	  
Approximately 3.6 billion people live in tropical or subtropical areas where Aedes 
mosquitos can carry Zika, dengue, Chikungunya and yellow fever viruses and a risk for 
epidemic transmission exists. However, the epidemiological data for ZIKV has only 
recently started to accumulate. For many years, ZIKV circulated in sylvatic cycles 
between non-human primates and mosquitoes in Asia and Africa, causing only sporadic 
human cases. The transition to human-mosquito-human cycles is a prerequisite for virus 
transmission in urban environments. Decades after its discovery, the first ZIKV 
outbreak was detected in 2007 on Yap Island in Oceania, where the overall infection 
rate (IgM positivity) was as high as 74%, and 37% of those infected were symptomatic  
(111). A new outbreak was reported in French Polynesia in 2013, where a serosurvey 
conducted after the outbreak revealed an infection rate of 50-60% with 30 000 
symptomatic infections (112). This outbreak was thought to be a new introduction from 
Asia unlike the virus on Yap Island (113). The outbreaks occurred in previously 
unaffected areas, and from French Polynesia, ZIKV continued to spread to neighboring 
islands, affecting New Caledonia, Cook Island and the Easter Islands in early 2014  
(114-116). A notifiable outbreak occurred in Martinique in 2015-2016, where 
autochthonous circulation of ZIKV was confirmed, and the cumulative number of cases 
was over 32 000 on an island of 400 000 inhabitants (117). 
Phylogenetic analyses show that ZIKV was first introduced to South America in Brazil 
most likely between May 2013 and December 2013 through a single introduction  
(118). The first cases of undefined febrile illness were reported in the beginning of 
2015, and the first confirmed ZIKV cases of the epidemic were reported in May 2015 in 
Brazil. Retrospectively, clusters of disease characterized by rash were reported in 
northern Brazil in 2014. By the end of January 2016, 30 000 cases had been reported in 
Brazil. The epidemic seemed to have peaked in mid-July 2015, with over 90% of the 
cases reported from Bahia state (118). A striking turn in the epidemic occurred between 
November 2015 and January 2016, when almost 5,000 suspected cases of microcephaly 
were reported in Northeast Brazil. An unusual increase in the number of neurological 
complications (Guillain-Barré syndrome) was also noticed retrospectively after the 
outbreaks in French Polynesia and Martinique, but it was not until the epidemic in 
Brazil that the causal relationship of ZIKV and microcephaly in fetuses and newborns 
was suspected. Data of the causal relationship accumulated and the WHO declared the 
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ZIKV epidemic to be a Public Health Emergency of International Concern (PHEIC). 
The cumulative number of confirmed autochthonous ZIKV cases in Brazil was 134 000 
by July 2017. The incidence rate for suspected and confirmed cases was 171.19/100 000  
(119). Almost 3000 confirmed congenital Zika syndrome cases in newborns have been 
reported (120). 
In September 2015, ZIKV continued to spread from South America northwards to 
Central America, reaching Mexico in November 2015 and Florida in North America 
late 2016. In 2015, 61 cases were confirmed in North America in travelers returning 
from affected areas. During 2016-2017, 225 autochthonous cases were confirmed 
(incidence rate 0.06), and 5 500 cases were imported. Zika virus congenital syndrome 
was confirmed in 91 newborns in North America (120). These numbers exclude 
pregnant women, which account for 2 000 cases of possible ZIKV infection (121). 
Zika virus has been circulating in Asia for the past 6-60 years, but no severe epidemics 
have emerged. In Europe, only imported cases have been reported in travelers. The first 
case was a German traveler returning from Thailand in November 2013. Large 
outbreaks are not expected, but since Aedes albopictus circulates in southern Europe, 
autochthonous transmission is possible after introduction during a hot season. Imported 
cases have been reported from all over Europe, including Finland (traveler returning 
from the Maldives in June 2015 (122)), Sweden and Denmark. In 2015, the epidemic 
strain returned back to its place of origin, Africa, where only sporadic cases had been 
reported. In Cape Verde, 5 000 suspected cases were reported from September to 
December 2015.  
To date, 48 countries and territories in the Americas have confirmed vector-borne 
transmission of ZIKV (Figure 7). Of over 570 000 suspected autochthonous cases, 214 
000 have been confirmed in total in North and South America. A total of 6 000 ZIKV 
infections have been confirmed in travelers, the total number of deaths related to ZIKV 
has reached 20 (excluding Guillain-Barré and congenital syndrome), and a total of 3 
400 cases of microcephaly in newborns have been reported. The epidemic in the 
Americas has ended, and in November 2016, the WHO declared that the ZIKV 
epidemic was no longer a PHEIC. 
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Figure 7. Countries with current Zika virus transmission. ECDC’s adaptation of the WHO's Zika 
virus country classification scheme (123). 
	  
Ecology	  and	  transmission	  	  
Flaviviruses are transmitted through arthropod vectors, mainly by mosquitos and ticks. 
Aedes spp. mosquitos are the most common vectors for DENV and YFV, and Culex 
spp. mosquitos for WNV and JEV. Aedes aegypti and Aedes albopictus have been 
shown to be the major vector species for ZIKV transmission, but the virus has also been 
isolated from several other Aedes species (124). 
Ectoparasitic ticks are obligate blood-feeding arthropods in the class Arachnida. The 
class is divided into three families, two of which transfer diseases to humans: Argasidae 
and Ixodidae. Ticks in the family Ixodidae are hard-bodied and more voracious than 
ticks in the family Argasidae, which gives the pathogen a greater chance to infect the 
host. Most of the vectors for tick-borne flaviviruses are Ixodes ticks, but Haemaphysalis 
inermis and Dermacentor reticulatus may also carry these pathogens (125).  
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Tick-­‐borne	  encephalitis	  virus	  
Ixodes ricinus and Ixodes persulcatus are the main vector species for TBEV in Europe 
and Asia; the European subtype is typically transmitted by I. ricinus and the Siberian 
and Far Eastern by I. persulcatus. Ticks go through three developmental stages in their 
life cycle: an adult female tick lays thousands of eggs, which develop into larvae, 
nymphs and mature females or males; each of these transitions requires a blood meal  
(126). The life cycle from larvae to adult varies from one to three years, depending on 
the climate. The transmission cycle of TBEV in ticks is dependent on many aspects in 
the existing microclimate. Nymphs require a minimum of +7°C and larvae +10°C for 
activity. Ticks also require a certain humidity for active questing. TBEV is preserved in 
nature through a cycle involving ticks and wild vertebrate hosts (Figure 8).  
 
 
 
Figure 8. TBEV transmission in nature. 
 
The virus resides in areas where ticks and their hosts co-exist in stable populations. 
Small rodents such as voles serve as amplifying hosts for TBEV. In addition to their 
role as vector, ticks are also considered to be important reservoirs of the virus (127). 
TBEV is maintained in tick populations by ticks feeding on infected animals as well as 
through transovarial (adult to eggs), transstadial (from one developmental stage to 
another), or non-viremic transmission between co-feeding ticks (128-130). TBEV can 
be transmitted from one tick to another when feeding on the same animal in close 
proximity. Co-feeding is considered an important form of TBEV transmission between 
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nymphs and larvae (131). This transmission cycle is dependent on delicate climate 
conditions at the ground level being favorable for nymphs and larvae to be active at the 
same time. Large mammals are usually accidental hosts and are not considered 
important sources of TBEV infection, because they experience low and short viremia, 
yet they play a role in the amplification of the tick population. Humans are dead-end 
hosts that play no role in natural TBEV circulation (132).  
The tick gut lacks digestive enzymes, which favors the survival of ingested micro-
organisms. The saliva of blood-feeding ticks contains many pharmacologically active 
molecules that help bypass the host immune defense, including anti-coagulants, 
inhibitors of platelet aggregation, local anesthetics and anti-inflammatory compounds 
(133). TBEV can also be transmitted via the consumption of unpasteurized goat, cow or 
sheep milk. TBEV remains infectious in unpasteurized milk and milk products, such as 
cheese and yogurt for several days (134). Food-related epidemics occur sporadically  
(135-137). 
 
Zika	  virus	  
The transmission profile of ZIKV differs greatly from TBEV. Mosquitoes are more 
numerous than ticks, and they have a shorter life span with populations that can be 
established in suitable conditions fairly easily. Unlike in TBEV transmission, humans 
can act as reservoir for the virus and transmit the virus further. In the place of its origin, 
ZIKV is maintained in sylvatic cycles between non-human primates and mosquitoes 
(Figure 9). Other species, such as bats, goats and rodents, have been found to be 
positive for ZIKV antibodies in serosurveys, but they likely play minor roles as 
reservoirs for the virus. In Yap Island and French Polynesian outbreaks, ZIKV was 
shown to circulate between humans and mosquitoes, which suggests that the virus has 
adapted to humans as a reservoir host and that the transmission cycle shifted from 
sylvatic to human-mosquito-human.  
Zika virus has been isolated from several mosquito species: Ae. africanus, Ae. 
luteocephalus, Ae. aegypti, Ae. vitattus and Ae. furcifer (138-140). During the Yap 
Island outbreak in 2007, Ae. hensilii was the predominant species on the island, but 
ZIKV could not be detected from any mosquitos (141). ZIKV was first isolated in Ae. 
aegypti in Malaysia in 1966 (139). Virus isolation from a male Ae. furcifer suggests 
vertical transmission, which could be important for maintaining the virus in nature  
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(142). However, even though the virus has been isolated from several species, Ae. 
aegypti is considered to be the most capable of transmitting the virus (8). 
Mosquitoes prefer hot and humid environments with standing water to lay their eggs, 
most commonly ponds, marshes and wetland habitats. However, mosquitoes can also 
successfully grow in number outside their natural habitats. Urban environments provide 
perfect conditions for mosquitoes, and, with high population densities, they also provide 
a setting for virus transmission. 
 
 
 
Figure 9. ZIKV transmission in nature. ZIKV cycles between non-human primates and mosquitoes, 
which can be transmitted through urban cycles between humans and mosquitoes as well as human-to-
human contacts. 
 
ZIKV can also be transmitted through various non-vector-borne means. The virus 
remains detectable in many body fluids, which renders sexual transmission possible 
(143). Perinatal transmission was reported during the outbreak in French Polynesia 
(144). Zika virus has also been transmitted through blood transfusions (145). The most 
striking mode of Zika virus transmission is likely the maternofetal route. Although it 
has been shown to occur with other arboviruses, such as DENV, WNV and CHIKV, 
prenatal ZIKV infections may result in severe adverse pregnancy outcomes.  
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Clinical	  picture	  and	  pathogenesis	  
Tick-­‐borne	  encephalitis	  
Characteristics of symptomatic infections vary depending on the virus subtype. The 
typical course for European subtype TBEV infection is biphasic, where the first phase is 
characterized by mild influenza-like symptoms that often pass without TBE diagnosis. 
Approximately one week after a tick bite (or the consumption of raw milk products), the 
first phase begins with abrupt uncharacteristic symptoms, such as fever, headache, 
nausea, vomiting and myalgia, and the patient is viremic. This phase usually lasts for 5 
days (2-10 days) and is followed by a symptomless interval of approximately one week 
(1-33 days) (146,147). In the first phase, thrombocytopenia, leukopenia and slightly 
elevated serum transaminase levels can be seen. In one third of the patients, the disease 
progresses to the second phase with neurological symptoms of differing severity, as the 
virus enters the central nervous system (CNS) (148). Encephalitic symptoms such as 
ataxia, dysphasia, altered consciousness and paralysis of the cranial nerve and 
respiratory muscles are typical (148). During the second phase, leukocytosis and 
pleocytosis in CSF are observed (147). In up to 18% of patients, MRI shows 
abnormalities in the thalamus, cerebellum, brainstem and nucleus caudatus (149). The 
disease severity increases with age, and severe forms are rare in young children. In 
addition to age, the severity of the disease in the acute phase, low neutralizing antibody 
titers and IgM response in CSF are associated with more severe forms of TBE 
(146,150). Approximately 20-40% of patients have been reported to suffer from long-
term sequelae up to one year after onset. These include different CNS dysfunctions, 
such as impairment of memory and decreased ability to concentrate, and occasionally 
even persisting spinal nerve paralysis (146). The case fatality rate in TBEV-Eur 
infections is <2%. Infections with the Siberian subtype of TBEV causes often a chronic 
form of the disease that is usually monophasic. Case fatality rates are reported to be 2-
8% for TBEV-Sib infections; death usually occurs 3-7 days after onset of the disease 
(14,147,148). The onset of the disease in the Far Eastern type of TBEV infection is 
more often gradual than acute. Typical first-phase symptoms are followed by a stiff 
neck, sensorial changes, visual disturbances and variable neurological dysfunctions. In 
fatal cases, death occurs within the first week after illness onset. The fatality rate is 
reported to be up to 20% for Far Eastern TBE (151). However, these rates may be 
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biased by the different standards of reporting and medical treatments available in the 
European and Far Eastern regions.  
Langerhans dendritic cells are the primary targets of vector-mediated flavivirus 
infection. Tick and mosquito saliva contain compounds that modulate the innate 
immune responses of the first infected cells, thus facilitating the virus infection 
(152,153). Infected dendritic cells migrate to draining lymph nodes from which the 
infection spreads to other organs, the spleen, liver and kidney, causing viremia. The 
major event in TBEV pathogenesis is the entry of the virus into the CNS and brain, 
which is characterized by neuroinflammation and breakdown of the blood-brain-barrier 
(BBB). The BBB is a selective semi-permeable physical barrier between the blood 
circulation and the brain that protects the brain from many pathogens. The BBB consists 
of epithelial cells that are connected through tight junctions formed by transmembrane 
proteins (such as occludin and claudins) as well as glial cells, neurons and pericytes 
(154). Upon infection, the inflammatory responses to viruses may lead to increased 
permeability of the BBB. Viruses have been suggested to cross the BBB via direct 
infection, trans- and paracellular transport or the Trojan-horse mechanism (155). 
Another means for entry to the CNS is retrograde axonal transport. TBEV has been 
shown to increase the permeability of the BBB, and breakdown of the BBB does not 
seem to be a prerequisite for TBEV entry into the brain. Rather, the breakdown seems 
to occur when the virus is already in the brain (156). It was recently suggested that 
TBEV utilizes the neuronal mRNA transport system and subsequently affects the 
outcome of the disease (157). 
Zika	  virus	  disease	  
As for many flaviviruses, Zika virus infection often appears asymptomatic. Clinical 
illness is usually mild and lasts for one week. Characteristic symptoms include fever 
with maculopapular rash, conjunctivitis, myalgia and headache (8). After the outbreaks 
in French Polynesia and Brazil, neurological complications have been described for 
ZIKV infections. In adults, ZIKV disease can result in Guillain-Barré syndrome (GBS), 
meningoencephalitis or myelitis (158,159). GBS is a neuromuscular disease in which 
the immune system damages peripheral nerve cells, affects motor functions and can 
cause paralysis. GBS has been reported worldwide and typically arises after viral or 
bacterial infections (160). The incidence of GBS is reported to be approximately 
1.1/100 000 annually (161). The risk of acquiring GBS after ZIKV infection is 
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estimated to be 0.24/1000 infections, with both symptomatic and asymptomatic ZIKV 
infections combined. The risk increases with age, and men are more often affected than 
women (95). In a study conducted with Colombian patients, a prolonged period of 
ZIKV shedding in urine was found to be connected with the onset of GBS. 
Additionally, a potential relationship with previous DENV infection was reported in 
Colombian ZIKV patients with GBS (162). 
Virological and epidemiological data have shown the causal relationship of ZIKV 
infection and microcephaly (163,164). Zika virus RNA can be detected in the placenta 
and amniotic fluid, as well as in the brain and other organs of fetuses. Microcephaly is a 
fairly uncommon condition, defined by a developmental defect of the brain with 
significant reduction in the brain circumference. Congenital microcephaly may be 
caused by accelerated apoptosis or reduced neuronal proliferation (165). Reports 
suggest that the risk is increased if the mother is infected during the first trimester, but 
adverse pregnancy outcomes have also been reported from infections during the second 
or third trimester (166).  
Thus far, little is known about the mechanisms by which ZIKV establishes a persistent 
infection in certain cells. Zika virus crosses the placenta from mother to fetus and the 
BBB to infect neurons, and ZIKV has been shown to have tropism for cells of the brain, 
particularly neural progenitor cells and cortical neurons, as well as many cell types in 
the reproductive system (167-169). Primary placental macrophages, called Hofbauer 
cells, together with cytotrophoblasts, have been shown to be permissive for ZIKV 
infection (170). Hofbauer cells have access to fetal blood vessels and may facilitate 
transfer or dissemination of the virus to the fetal brain. Mladinich and others showed 
recently that ZIKV persistently infects and replicates in primary human brain 
microvascular endothelial cells without cytopathology. Furthermore, ZIKV was 
released basolaterally from these cells, suggesting a direct means to cross the BBB  
(171).  
A phenomenon called antibody-dependent enhancement (ADE) facilitates the 
antibodies from previous DENV infection with different serotypes to the binding and 
internalization of virus particles via the Fc receptors attached to leukocytes. 
Additionally, immature virus particles are infectious through ADE. DENV antibodies at 
sub-neutralizing titers have also been shown to enhance ZIKV infection (172-174). In 
addition, monoclonal antibodies to DENV were shown to bind, but not to neutralize 
ZIKV, thus promoting infection through ADE. Since DENV and ZIKV are circulating 
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in the same geographical areas, ADE seems possible, but the impact on disease severity 
needs to be elucidated.  
 
Diagnostic	  tests	  
Flaviviruses are highly cross-reactive, which makes serological assays challenging. 
Other flavivirus infections or vaccinations (JEV, TBEV, YFV, and WNV) can result in 
false-positive results or homologous IgM responses, and with both TBE and ZIKV 
diseases, their clinical pictures resemble that of many others. ZIKV circulates in the 
same areas as DENV and mosquito-borne alphavirus chikungunya (CHIKV), and 
patients can even be infected with two of the pathogens from the same mosquito. The 
patient is viremic from day 4 to 10, and IgM antibodies can be detected in blood for 
several weeks. In flavivirus diagnostics, IgM antibody positivity is verified by IgG 
antibody conversion. Previous DENV infection can suppress ZIKV IgM antibodies. 
Serological tests used in diagnostics include enzyme immunoassays (EIAs), 
immunofluorescence assays (IFAs), hemagglutination inhibition tests (HIs) and virus 
neutralization tests (NTs), which are used as a reference test. Viral nucleic acids can be 
detected by RT-PCR; however, for TBE diagnostics, this is not usually the case, since 
the patient is viremic only in the first phase, which often goes undiagnosed as a mild 
flu-like disease, and the virus is cleared from blood before the second phase. ZIKV 
RNA or antigens can be detected from several body fluids (serum, urine, saliva, or 
whole blood) and tissues from early disease onset. It has also been shown that ZIKV 
persists in body fluids and can be detected in saliva or semen weeks and even months 
after disease onset (175).  
 
Treatment	  and	  prevention	  
There is no effective antiviral treatment for TBE, and patients are treated according to 
their symptoms. TBE can be prevented by vaccination. TBE vaccines contain formalin-
inactivated virus and are widely used across Europe. Wearing protective clothes and 
repellents and avoiding the consumption of unpasteurized milk products from endemic 
areas are effective preventative measures (176). The virus is transmitted directly after a 
tick bite, which makes tick removal an uncertain measure of prevention for TBE. 
Increasing people’s knowledge of TBEV in endemic areas and vaccination are 
important for the prevention of TBE. 
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Similar to TBE, there is no effective antiviral treatment for Zika virus disease. 
Currently, there are several candidate ZIKV vaccines. A DNA-based vaccine is in phase 
2 clinical trials in the Americas, and a purified inactivated virus vaccine is in phase 1 
(177). A live-attenuated and several investigational DNA, RNA and recombinant 
vaccines are under development (178). Effective non-specific prevention measures 
include protective clothing, repellents and removing or emptying water-containing 
items from surroundings. As ZIKV is a risk for pregnant women or women planning to 
get pregnant, travel should be planned according to the latest travel recommendations 
(179).  
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AIMS	  OF	  THE	  STUDY	  
 
We isolated two neuropathogenic flaviviruses, Zika virus and tick-borne encephalitis 
virus, from human brains. Our aims were: 
•   to characterize the ZIKV and TBEV cases and analyze the subsequent viral isolates;  
•   to provide potential proof that congenital ZIKV infections are a causative agent of fetal 
brain abnormalities; 
•   to screen and study the antiviral potential of several compounds against the isolated 
ZIKV; and 
•   to characterize the new ZIKV isolate by studying its cell tropism in comparison with 
related epidemic strains. 
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MATERIALS	  AND	  METHODS	  	  
Materials	  
Cells	  	  
Cells were maintained in Eagle’s Minimal Essential Medium (MEM); Dulbecco's 
Modified Eagle Medium (DMEM or D-MEM); Roswell Park Memorial Institute 
(RPMI) 1640 supplemented with glutamine, 100 units/ml penicillin, 100 µg/ml 
streptomycin and 10% fetal bovine serum (FBS); DMEM-F12 medium supplemented 
with 50 U/ml PenStrep, 2 mM l-glutamine, 10% FBS, and 0.25% sodium bicarbonate 
(Sigma-Aldrich); or in a specific culture medium (Table 2) at 37 °C with 5% CO2 
(human cell lines) or at room temperature (mosquito cell lines). During infections, 
media contained 2% FBS.  
For infections (III), the cells were grown in T25 flasks to 80% confluency or in 
multiwall plates (6, 24 and 96) (II). Cells were infected with a multiplicity of infection 
(MOI) of 0.1 or 0.2 (III) for 1 h at +37°C (human cell lines) or room temperature 
(mosquito cell lines), after which the cells were washed once with phosphate buffered 
saline (PBS), and then cell culture media was added. Thereafter, the cells were 
incubated for three days either at +37°C (human cell lines) or room temperature 
(mosquito cell lines). Cells were infected with an MOI of 8.5 (II) without removing the 
virus stock.  
 
Viruses	  
The ZIKV FB-GWUH-2016 strain was isolated from a fetal brain in VE6 and SK-N-SH 
cells (I) and was passaged once in VE6 cells prior to its use in other studies (II), or it 
was used directly after isolation in SK-N-SH cells (III). Fetal brain tissue was 
homogenized in 0.2 Dulbecco’s bovine serum albumin (BSA) and was then used to 
inoculate SK-N-SH cells. Viral RNA and the cytopathic effect (CPE) were monitored 
using an in-house ZIKV RT-PCR (reverse transcription polymerase chain reaction) 
assay, and the presence of viral antigens was determined on day 6 post-inoculation by 
immunofluorescence assays (IFAs). The prototypic ZIKV MR766 strain was obtained 
from Dr. Jonas Schmidt-Chanasit (Berhard-Nocht-Institut für Tropenmedizin, 
Hamburg, Germany), and it was propagated twice in VeroE6 cells. Freeze-dried Zika 
virus strains H/PF/2013 (clinical isolate from French Polynesia 2013; H/PF) and 
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MRS_OPY_Martinique_PaRi_2015 (clinical isolate from Martinique 2015; MRS OPY) 
were obtained from EVA (European Virus Archive, Marseille, France), and they were 
propagated once in VeroE6 cells, obtaining passages 2 and 6, respectively (III).  
Siberian subtype TBEV was isolated from a human brain in SK-N-SH cells (IV). Virus 
isolations were attempted from a diseased case’s cerebellum tissues. Cerebellum tissue 
was homogenized in 0.2 Dulbecco’s BSA and was then used to inoculate SK-N-SH 
cells. CPE and viral RNA were monitored using RT-PCR, and the presence of viral 
antigens was determined on day 6 post-inoculation via immunofluorescence assays 
(IFAs). 
 
Antiviral	  agents	  	  
Obatoclax, MK2206, SNS-032, dinaciclib and gemcitabine were purchased from 
Selleck Chemicals, USA. SaliPhe was synthesized by Jef De Brabander's group as 
described previously  (180). Each compound was dissolved in 100% dimethyl sulfoxide 
(Sigma-Aldrich, MO, USA) to obtain a 10 mM stock solution.  
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Table 2. Cell lines used in these studies 
Organism, 
Cell line 
Anatomic origin Source Culture media Study    
Human     
HaCaT keratinocyte cell line from 
adult human skin 
Kindly provided by Prof. Dr. Petra 
Boukamp and Prof. Dr. Norbert E. 
Fusenig, DKFZ, Heidelberg, 
Germany 
D-MEM 
 
III    
HFSF human foreskin dermal 
fibroblast 
Kindly provided by Dr. Magdalena 
Eisinger, Memorial Sloan-Kettering 
Cancer Center, New York, NY, 
USA 
D-MEM 
 
III    
MRC-5 fetal lung fibroblast ATCC® CCL-171™ MEM III    
SK-UT-1 uterus epithelial grade III, 
mesodermal tumor (mixed); 
consistent with 
leiomyosarcoma 
ATCC® HTB-114™ MEM III    
JAR placenta epithelial 
choriocarcinoma 
ATCC® HTB-144™ RPMI 1640 
 
III    
HUVEC umbilical vein/vascular 
endothelium 
ATCC® CRL1730™ EBM MV III    
HMEC-1 dermal microvascular 
endothelium, newborn 
ATCC® CRL-3243™ EBM MV III    
A498 kidney epithelial carcinoma ATCC® HTB-44™ MEM III    
H-2 glioblastoma cell line from a 
rapidly expanding local brain 
tumor 
(181) MEM 
 
III    
H-4 brain epithelial neuroglioma ATCC® HTB-148™ D-MEM 
 
III    
SK-N-SH neuroblastoma ATCC® HTB-11™) MEM I, IV    
RPE retinal pigment epithelium ATCC® CRL-4000™ D-MEM/F12 
supplemented with 
sodium bicarbonate 
II    
Nonhuman     
Vero E6 Green monkey kidney ATCC® CRL-1586™ MEM I, II, 
III 
   
        
AE Aedes aegypti Kindly provided by X. de 
Lamballerie, Université de la 
Méditerranée & Institut de 
Recherche pour le Développement 
L-15 supplemented 
with tryptose 
phosphate broth 
III    
C6/36 Aedes albopictus ATCC® CRL-1660 L-15 III    
AP-61 Aedes pseudoscutellaris Kindly provided by X. de 
Lamballerie 
L-15 supplemented 
with tryptose-
phosphate broth 
III    
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Methods	  
RNA	  extraction	  and	  quantitative	  RT-­‐PCR	  (I-­‐IV)	  
RNA was extracted using a Viral RNA Mini Kit according to the manufacturers’ 
instructions (Qiagen, Hilden, Germany). ZIKV RNA was monitored using a ZIKV-RT-
qPCR targeting the NS5 protein  (163). TBEV RT-PCR was performed as described 
previously  (182). Viral RNA loads were quantitated using a synthetic ZIKV or TBEV 
RNA transcript as a standard curve. Briefly, RNA was generated from the last 3500 
nucleotides of the TBEV (strain Kumlinge A52) and ZIKV NS5 genes (strain MR766) 
and was then cloned into pGEM®-T vector (Promega, Madison, USA) using the 
RiboMAX™ Large Scale RNA production system with SP6 polymerase (Promega, 
Madison, USA) according to the manufacturer's instructions. The viral loads were 
calculated from pre-quantitated synthetic RNA transcripts. 
Cellular RNA was extracted using a RNeasy Mini Kit (Qiagen) according to the 
manufacturers’ instructions. The expression of cellular MxA (183) (forward primer: 5’-
AGTATGGTGTCGACATACCGGA-3’ and reverse primer: 5’- 
AGTATGGTGTCGACATACCGGA-3’), and RNA polymerase II (184), which was 
used as a housekeeping gene, (forward primer: 5’-GCACCACGTCCAATGACAT-3’ 
and reverse primer: 5’-GTGCGGCTGCTTCCATAA-3’) were analyzed from 50 ng of 
total cellular RNA using a qScript One-Step SYBR Green RT-qPCR kit (Quantabio, 
Beverly, MA, USA). The expression of cellular IFIT1 (forward primer: 5’-
TCTCAGAGGAGCCTGGCTAA-3’ and reverse primer 5’-
TGACATCTCAATTGCTCCAG-3’, Sigma Aldrich), IFIT2 (forward primer: 5’-
AAGAGTGCAGCTGCCTGAA-3’ and reverse primer: 5’-
GGCATTTTAGTTGCCGTAGG-3’, Sigma-Aldrich), and IFIT3 (forward: 5’-
GAACATGCTGACCAAGCAGA-3’ and reverse: 5’-CAGTTGTGTCCACCCTTCCT-
3’) were analyzed using a qScript One-Step SYBR Green RT-qPCR kit (Quantabio, 
Beverly, MA, USA). Samples were analyzed in duplicate. The relative RNA levels were 
calculated, and the results were represented as fold induction compared to the control.  
	  
Virus	  titrations	  (II,	  III)	  
Supernatants were collected 48 hours post-infection (hpi) from ZIKV-infected RPE 
cells (II) or 3 days post-infection (dpi) ZIKV-infected cells (III). Infectious virus 
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particle amounts were determined by plaque assays (II) or end-point titration assays 
(III). In the plaque assays, virus-containing supernatants were diluted in PBS and added 
to VeroE6 cells in 6-well plates for 1 h. Virus was removed and cells were overlaid with 
1% melted agarose in MEM with 2% FBS, 2 mM l-glutamine, and 50 units/ml PenStrep 
for 4-6 days. Cells were fixed with 10% formaldehyde for 30 min and stained with 
0.1% crystal violet in 2% ethanol. In the end-point titration assays, logTCID50 values 
were determined using the method of Reed and Muench (185). Briefly, VeroE6 cells 
were plated in 96-well plates for 24 h prior to infection, and they were then infected in 
quadruples of each virus dilution from three independent experiments. CPE was 
observed, and logTCID50 values were calculated. 
	  
Immunofluorescence	  assay	  (IFA)	  (I-­‐IV)	  
IFA slides from ZIKV and TBEV-infected cells were prepared 6 dpi (I, IV) or 3 dpi 
(III), and cells were fixed with 100% ice-cold acetone. RPE cells were grown on 
coverslips, treated with the antiviral compounds being studied, infected and fixed with 
80% ice-cold acetone (II). ZIKV antigens were stained with ZIKV IgG-positive patient 
serum (1:40 dilution I; 1:80 dilution II-III) or mouse monoclonal antibody against the 
TBEV E protein (kindly provided by Dr. Matthias Niedrig, Robert Koch Institute, 
Berlin, Germany) and were then visualized with Fluorescein (FITC)-conjugated goat 
anti-human IgG (H+L) or rabbit anti-mouse immunoglobulin (Jackson 
ImmunoResearch, West Grove, PA, USA) secondary antibody. The nuclei were stained 
with Hoechst33342.   
	  
Next	  generation	  sequencing	  (NGS)	  (I,	  IV)	  
RNA was extracted from SK-N-SH cell supernatant 5 (I; IV, case 1) days after 
inoculation with a brain tissue sample using a QIAamp viral RNA kit (Qiagen) without 
carrier RNA. The cerebellum sample from case 2 (IV) was homogenized using a 
MagnaPure homogenizer for 1 min at 3000 rpm and was then centrifuged through a 0.8-
µm PES filter (Sartorius Vivaclear Mini). The homogenized sample was treated with an 
ApoH-CaptoVIR kit (ApoH Technologies, La Grande-Motte, France), followed by 
nuclease treatment for 2 h at +37°C using a micrococcal nuclease (New England 
Biolabs, MA, USA) and benzonase (Millipore, MA, USA). RNA was extracted with 
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TriSure reagent (Bioline, London, UK). Ribosomal RNA was removed using a Ribo-
Zero Gold rRNA Removal Kit for Epidemiology (Illumina, CA, USA) according to the 
manufacturer’s instructions. The homogenization and RNA extraction of a TBEV-
positive tick pool was described in ref. (186). All RNA samples were treated with 
DNAse I (Thermo Scientific, MA, USA).  
TBEV RNA (IV) was reverse transcribed and amplified using a WTA2 Complete whole 
transcriptome amplification kit (Sigma-Aldrich). The sequencing libraries for NGS 
were prepared using an Illumina NexteraXT sample preparation kit (Illumina) according 
to the manufacturer´s instructions. A ZIKV NGS library was prepared using an Illumina 
TruSeq Stranded Total RNA LT with Ribo-Zero Gold sample preparation kit (Illumina) 
according to the manufacturer´s instructions. 
A NEBNext Library Quant Kit for Illumina (New England Biolabs) was used for library 
quantitation. Sequencing was conducted using an Illumina MiSeq system with a MiSeq 
Reagent Kit v2 (I) or v3 (IV), generating 150 or 300-base pair (bp) paired-end reads. 
Reads were demultiplexed, adapter sequences were removed, and FASTQ files were 
produced using the MiSeq reporter. De novo sequence assembly was conducted using 
the MIRA sequence assembler (version 4.9.5) (187,188), followed by the re-mapping of 
sequence reads to the de novo assembled consensus sequences using the Bowtie2 
algorithm (189) implemented in UGENE software (190). 
	  
Phylogenetic	  analysis	  
All available ZIKV complete genomes or complete coding regions were downloaded 
from GenBank (27/Feb/2016) (I). Three alignments were constructed for TBEV 
phylogenetic analysis (IV): one that contained all available TBEV-Eu complete coding 
sequences, one that contained all available TBEV-Sib complete coding sequences, and 
one that contained representatives of all major clades of TBEV Eu, Sib and FE 
(GenBank search May 2017). The sequences were aligned using the ClustalW algorithm 
implemented in MEGA6 software (191), and the best-fit substitution model was sought. 
The analyses were conducted using a GTR+G (I) or GTR+G+I (IV) substitution model, 
an uncorrelated log-normal distributed relaxed molecular clock and a Bayesian skyline 
demographic model (192). The Bayesian analysis was run for 100 million states and 
sampled every 1000 states. Posterior probabilities were calculated with a burn-in of 10 
million states and checked for convergence using Tracer version 1.6 (193). The 
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phylogenetic trees were constructed using the Bayesian Markov chain Monte Carlo 
method implemented in BEAST version 1.8.0 (194).  
	  
Cell	  viability	  assay	  (II)	  
Typically, 40,000 RPE cells were seeded per well and grown for 24 h. The antiviral 
compounds being studied were added to the cells in 3-fold dilutions at seven different 
concentrations starting at 10 µM. No compounds were added to the control wells. The 
cells were infected with the viruses at an MOI of 0.5-8.5, depending on the strain. When 
virus-induced CPE was observed (48 hpi), cell viability was measured using Cell Titer 
Glo assays (CTG; Promega, Madison, WI, USA). The luminescence was measured with 
a Hidex sense microplate reader (Hidex Oy, Turku, Finland). The half maximal 
cytotoxic concentration (CC50), the half maximal effective concentration (EC50) and 
selectivity index (SI) were determined for each compound as described previously in 
ref. (195). 
In the drug combination experiment, RPE cells were treated with increasing 
concentrations of one drug and a constant concentration of another. The cells were 
infected with ZIKV at an MOI of 8.5. Cell viability was measured 48 hpi using the CTG 
assay. To test the synergy of the drug combinations, a zero interaction potency (ZIP) 
model was used to analyze the observed responses in comparison to the expected 
combination responses. Drug combinations were classified as synergistic or antagonistic 
based on the deviations of the observed and expected responses. 
	  
Compound-­‐addition	  assays	  (II)	  
In time-of addition assays, 1 µM obatoclax, SaliPhe, or gemcitabine was added to 
ZIKV-infected (MOI 8.5) or mock infected RPE cells at 0, 2, 4, 6, 8 and 10 hpi. Cell 
viability was measured at 48 hpi using the CTG assay (Promega). In the second 
experiment, ZIKV-infected (MOI 8.5) RPE cells were treated with 1 µM obatoclax, 
SaliPhe, or gemcitabine at 0, 2, 4, and 8 hpi. After 2 h of treatment the media was 
exchanged with plain media. Cell viability was measured at 48 hpi using the CTG 
assay. 
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Gene	  expression	  profiling	  (II)	  
RNA was extracted from ZIKV- or mock-infected RPE cells 10 hpi using an RNeasy 
Mini kit (Qiagen, Hilden, Germany). Gene expression profiles were generated with an 
Illumina Human HT-12 v4 Expression BeadChip Kit as described previously. 
Differentially expressed genes between the samples and controls were determined using 
the Limma package in the Bioconductor suite for R  (196). The Benjamini-Hochberg 
multiple correction testing method was used to filter out differentially expressed genes 
based on a q-value threshold (q<0.05). Filtered data were sorted by logarithmic fold 
change (log2Fc). A heatmap was generated using Breeze, an in-house developed 
interface. Gene set enrichment analysis was performed using open-source software  
(197). 
	  
Metabolomics	  (II)	  
Metabolomics analysis was performed as described previously. Briefly, 10 µL of a 
labeled internal standard mixture and 0.4 mL of solvent (99% acetonitrile (ACN) and 
1% formic acid (FA)) were added to 100 µL of sample (cell culture media). The extracts 
were dispensed in OstroTM 96-well plates (Waters Corporation, Milford, USA) and 
filtered by applying vacuum at a delta pressure of 300-400 mbar for 2.5 min on a 
Hamilton StarLine robot’s vacuum station. Sample analysis was performed on an 
Acquity UPLC-MS/MS system (Waters Corporation, Milford, MA, USA). The 
detection system, a Xevo TQ-S tandem triple quadrupole mass spectrometer (Waters, 
Milford, MA, USA), was operated in both positive and negative polarities with a 
polarity switching time of 20 msec with electrospray ionization (ESI) at a capillary 
voltage of 0.6 kV for both polarities. The source temperature and desolvation 
temperature of 120°C and 650°C, respectively, were maintained constantly throughout 
the experiment. The Multiple Reaction Monitoring (MRM) acquisition mode was used 
to quantify the metabolites with an individual span time of 0.1 sec given in their 
individual MRM channels. Data acquisition, data handling and instrument control was 
accomplished using MassLynx 4.1 software. Data processing was performed with 
TargetLynx software, and metabolites were quantified by calculating curve area ratios 
using labeled internal standards (IS) (area of metabolites/area of IS) and external 
calibration curves. Metabolomics data were log2 transformed for linear modeling and 
empirical-Bayes-moderated t-tests using the Limma package. To analyze the differences 
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in metabolite levels, a linear model was fit to each metabolite. The significant 
metabolites were determined at a controlled Benjamini-Hochberg false discovery rate 
(FDR) of 10%. A heatmap was generated using the Pheatmap package  (198) based on 
log transformed profiling data. MataboAnalyst 3.0 was used to identify pathways 
related to ZIKV infection.  
	  
Caspase	  1,	  3/7,	  8	  and	  9	  activity	  assays	  (II)	  
Caspase-Glo-1, 3/7, 8 and 9 assays (Promega) were used to measure the respective 
caspase activities in the antiviral compound experiments at 40 hpi according to the 
manufacturer's instructions. The luminescence was measured with a Hidex sense 
microplate reader (Hidex Oy, Turku, Finland). 
	  
Phosphoprotein	  and	  cytokine	  profiling	  (II)	  
Cells were lysed 10 hpi, and phosphorylation profiles of 43 kinases and 2 kinase 
substrates were analyzed using the human phosphokinase array (R&D Systems) 
according to the manufacturer's instructions. Cytokines were analyzed from the media 
of ZIKV- or mock-infected un- or compound-treated RPE-cells at 48 hpi using a 
Proteome Profiler Human Cytokine Array Kit (R&D Systems) according to the 
manufacturer's instructions. The results were analyzed using ImageJ software. An at 
least 2-fold difference in the expression levels between mock and ZIKV-infected, 
compound-treated or ZIKV-infected/compound-treated samples was considered 
differentially expressed. 
	  
Statistical	  analysis	  (I-­‐IV)	  
Student’s t-test was used for all statistical analyses. A P-value of <0.05 was considered 
statistically significant. 
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RESULTS	  AND	  DISCUSSION	  	  
Isolation	  of	  ZIKV	  and	  TBEV	  from	  human	  brains	  (I,	  IV)	  
ZIKV	  
We monitored a case of a 33-year-old pregnant female who was suspected to have 
contracted Zika infection during the 11th week of gestation while travelling in Central 
America, most likely in Guatemala, in late November 2015. Prolonged maternal viremia 
was detected in the patients’ sera, showing positive RT-PCR results with approximately 
1 copy per ml of serum in samples taken at 16 and 21 weeks of gestation. Serologic 
evidence for ZIKV infection was obtained during week 17, showing a titer of more than 
1:2560 in a plaque reduction neutralization test (PRNT) performed in the US. Amniotic 
fluid was positive for ZIKV RNA at week 19. No evidence of microcephaly or other 
abnormalities was seen via ultrasonography performed 1, 4 and 5 weeks after resolution 
of the symptoms. However, there was a decrease in fetal head circumference from 16 to 
20 weeks of gestation. MRI performed at 20 weeks showed abnormal features in the 
developing brain: diffuse atrophy of the cerebral mantle, enlarged ventricles and a 
shortened corpus callosum. The pregnancy was terminated at week 21. Serum, blood, 
peripheral blood mononuclear cells, saliva, urine and plasma of the mother obtained 11 
and 13 days after termination were negative for ZIKV RNA (Figure 10).  
 
Figure 10. Timeline of symptoms and clinical and laboratory findings. Reproduced with permission 
from Driggers et al. NEJM 2016. 
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Post-mortem analysis showed abundant apoptosis primarily affecting the intermediately 
differentiated post-migratory neurons in the neocortex. In contrast, well-differentiated 
neurons in the basal ganglia and limbic regions appeared unaffected. In addition, white 
matter and the subventricular zone showed severe volume loss with axonal rarefaction 
and macrophage infiltrates. 
Zika virus isolations were attempted from the tissues of the affected mother and the 
fetus, in whom the presence of viral nucleic acids was detected by RT-PCR; the serum 
of the patient, fetal brain, placenta, fetal membranes/umbilical cord and spleen were 
used to inoculate SK-N-SH human neuroblastoma, Vero E6 green monkey kidney and 
C6/36 Aedes albopictus mosquito cells. A ZIKV strain designated FB-GWUH-2016 
(FB-GWUH, for short) was isolated from fetal brain tissue in human SK-N-SH cells 
and VE6 cells. The virus growth was more pronounced in the neuroblastoma cells from 
the day of inoculation compared to VE6 cells, which presented an initial lag phase of 
three days before substantial virus replication occurred. CPE was monitored and viral 
RNA load was determined daily from cell culture supernatants using an in-house ZIKV 
real-time RT-PCR (ZIKV-RT-qPCR) assay, and the presence of viral antigens was 
determined on day 6 post-inoculation via immunofluorescence assays (IFA) (Figure 
11). 
 
Figure 11. Isolation of the FB-GWUH-2016 strain from a fetal brain. Reproduced with permission 
from Driggers et al. NEJM 2016. 
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The complete genome sequence of the isolated virus was obtained by next generation 
sequencing (NGS) of the cell culture supernatant on day 5 post-inoculation. 
Phylogenetic analysis of the FB-GWUH (GenBank accession number KU870645) viral 
strain showed that the virus was a member of the Asian genotype and was closely 
related to ZIKV sequences previously obtained from Guatemala. FB-GWUH has 8-14 
amino acid mutations compared to previous virus strains from the Americas. Five of the 
mutations were specific to FB-GWUH compared to the other Guatemalan viruses 
sequenced at the time. Three of the amino acid mutations were specific for the three 
Guatemalan strains discussed here, and one amino acid substitution was a reversion to 
the African genotype (Figure 11). 
The magnitude of the ZIKV epidemic in the Americas was striking. Previous outbreaks 
had shown the capability of the virus to cause neurological manifestations, but the 
epidemic of microcephaly was unforeseen. The isolation of ZIKV FB-GWUH from 
affected fetus’ brain was considered a key piece of evidence in the search for causal 
relationship of ZIKV and microcephaly. The spread of ZIKV to a previously naïve 
population with favorable socio-economical structures has most likely considerably 
affected the course of the epidemic. The epidemiological and virological studies on 
ZIKV have multiplied by the hundreds during 2016 compared to the preceding time. 
Reports suggest that the ZIKV virus strains now circulating in the Americas could be 
more neuropathogenic and virulent than other strains. The ZIKV strains show cell 
tropism especially to undifferentiated neural progenitor and neural stem cells. The 
characteristic prolonged viremia and virus shedding from certain tissues is specific to 
ZIKV infection.  
The FB-GWUH strain showed unique amino acid differences when compared to ZIKV 
isolates from the same geographical area. Amino acid differences are also found from 
the virus sequence obtained directly from the brain tissue of the fetus compared to the 
sequence obtained from the blood of the expectant mother taken the day of the disease 
onset (Teemu Smura, unpublished results). These mutations in the nonstructural region 
seem to be indicative of selection when infecting the fetus. The impact of these 
mutations is to be investigated.  
The mechanism by which ZIKV crosses the placenta from infected mother to fetus is 
not yet fully known. It has been suggested that the virus particularly infects placental 
macrophages, Hofbauer cells, and traverses through the developing placenta to gain 
access to placental veins and subsequently the fetus. Disease severity in dengue 
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infections is related to secondary DENV infections through ADE. Intriguing question is, 
whether ADE would play a role in virus dissemination in the placenta. Primary 
infection with one DENV serotype provides lifelong immunity to the same but not 
different serotypes. In sub-neutralizing conditions, it enhances the secondary infection, 
potentially causing severe dengue with hemorrhagic fever or shock (199). DENV 
antibodies have also been shown to enhance ZIKV infections (172), which could have 
in part affected the course of the ZIKV epidemic. Whether it is the genetic differences 
of these viruses or the hosts, or both, that have had an impact on the epidemic, remains 
to be elucidated. 
 
TBEV	  
In 2015, two fatal cases were reported from a recently emerged TBE focus in the Kotka 
Archipelago, Finland. Both of the fatal cases, as well as two other (nonfatal) cases, were 
reported from the same small island of Kuutsalo. The first fatal case was a previously 
healthy 36-year-old female. She experienced a febrile illness that lasted for one week 
before the sudden onset of disturbed vision, severe headache and numbness of the right 
arm. Her MRI was normal. Two days later, she was admitted to a tertiary care unit due 
to disorientation and right hemiparesis. MRI showed indications of viral meningeal 
process in cortical sulcus regions, and CSF demonstrated pleocytosis. Her condition 
deteriorated rapidly, and a head CT scan revealed cerebellar herniation. The patient died 
after three days in the hospital. CSF and blood were positive for TBEV-IgM, and TBEV 
specific antibodies were detected by hemagglutination inhibition (HI) at a titer of 20.  
Post-mortem, massive brain edema and tonsillar herniation were detected. Severe signs 
of widespread viral encephalitis, such as meningeal and perivascular inflammation, 
neuronophagy and endothelial damage, were observed. A marked inflammation was 
observed throughout the CNS with lymphocytes, macrophages, plasma cells and 
microglial reactions (Figure 12). 
The medulla, cerebellum, spinal cord and spleen were positive for TBEV RNA by RT-
PCR (Figure 12). Virus isolation was successful from the cerebellum in SK-N-SH cells, 
but not in VE6 cells. Viral RNA copy numbers were monitored using TBEV RT-PCR, 
and the presence of viral antigens was determined on day 6 post-inoculation by 
immunofluorescence assays (IFA). A full genome sequence was obtained from the cell 
culture supernatant on day 6 by NGS. The isolated virus was of the Siberian subtype, 
53  
and phylogenetic analysis showed its close relationship to a previous isolate from the 
serum of an acute TBE patient in Latvia (Figure 13). 
 
G 
 
Figure 12. Pathological and virological findings. (A) MRI of case 1 demonstrated pathologically 
increased signal in cortical sulcus regions indicative of viral meningeal process. Hematoxylin and eosin 
(HE) staining of the frontal cortex of case 1 showed inflammation throughout the CNS from the spinal 
cord to the cortex (B) and cerebellum. Increased signal is shown in the MRI of case 2 in the facial nerves, 
cortical sulci radicular regions and cerebellar vermis (D). Neuropathological examination showed 
microscopically abundant perivascular lymphocytosis in the cerebellum of case 2 (E). TBEV RNA was 
detected in several parts of the brain of both cases and in the spleen of case 1 (C, F). The Siberian subtype 
of TBEV was isolated from the cerebellum of case 1, and the full-length genome was sequenced. The 
whole genome sequence of a new European subtype was obtained directly from the cerebellum of case 2. 
(G) A phylogenetic tree of the complete coding regions using the Bayesian MCMC method with a TN93-
G-I model of substitution, a lognormal relaxed clock model and a Bayesian skyline demographic model. 
Posterior probabilities are shown at each node. 
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Previously, a TBEV-positive I. ricinus tick pool was collected from a neighboring 
island, Haapasaari  (186). We subjected all RNA in this tick pool to metagenomic 
analysis, and a whole TBEV genome was obtained directly from the tick material; this 
tick TBEV sequence was almost identical to the sequence of the brain isolate. The two 
genomes have 3 nucleotide differences, which result in two amino acid substitutions: 
R868K in NS1 and V1452A in NS2B, suggesting virus adaptation either to the human 
brain or cell culture (Figure 13). 
 
 
Figure 13. Maximum clade credibility tree of a TBEV-Sib strain isolated in Kuutsalo and a whole 
genome obtained from an infected tick pool (arrow) in Haapasaari, Finland. 
 
Case 2 was a 66-year-old immunocompromised male with hypertension, diabetes and 
chronic lymphatic leukemia. The patient had persistent fever two weeks before 
hospitalization. At admission, he had developed tetraparesis and urinary retention. 
Increased signal was observed in the cerebellar vermis, facial nerves, cortical sulci and 
radicular regions in MRI (Figure 12). Pleocytosis was observed in CSF, but both CSF 
and serum were TBEV-IgM negative. CSF was IgM positive one week later. The 
patient had hypogammaglobulinemia, which likely aggravated the course of the disease 
and delayed serological diagnosis. The patient died after four weeks in the hospital. 
55  
Severe coronary disease, cardiac hypertrophy and atherosclerosis as well as 
bronchopneumonia were observed in the post-mortem examination. Disseminated 
encephalitis of viral origin was observed in the neuropathological examination: 
perivascular lymphocytosis continuing to the brain parenchyma, causing neuronophagy 
and glial reactivity. The frontal cortex, pons, medulla, radicular, spinal cord, and 
cerebellum were RT-PCR positive for TBEV (Figure 12). Virus isolation trials from the 
RNA-positive tissues were unsuccessful. However, through metagenomics, the whole 
virus sequence was obtained directly from the cerebellum. The virus was of the 
European subtype and was phylogenetically closely related to the previously described 
virus strain Kubinova, with the most common recent ancestor dating back hundreds of 
years (675, 95% CI 298-1003 years) (Figure 14). A TBEV-positive tick was collected in 
Kuutsalo in 2017, and the sequence analysis confirmed the virus to be of European 
subtype, and furthermore, highly similar to the genome sequenced from the cerebellum 
of case 2 (our unpublished results).  
TBE has spread to new areas in Finland during the past decade. The Kotka archipelago 
represents a newly established TBEV focus, since no cases were reported before 2010. 
Thereafter, 20 cases have been reported, two of which were fatal. Siberian subtype 
TBEV was already previously found in an unusual combination with I. ricinus ticks in 
the Kotka archipelago (186), which is why TBEV-Eur was a somewhat surprising 
finding as the causative agent of the second fatal infection. The coexistence of two 
TBEV subtypes was further confirmed by TBEV-infected tick collected in Kuutsalo, 
which makes the focus unique.  
There is a considerable infection pressure in this small focus, given that the virus was 
found in a tick in the same area, where TBE cases were reported. The underlying 
reasons for the seemingly high virulence of the two cocirculating subtypes remain to be 
elucidated. Several important risk factors for disease severity and development in 
flavivirus infections have been identified in epidemiological studies. Age and gender 
are predisposing factors for severe disease outcome in many flavivirus infections (the 
young are more susceptible to DENV and JEV, while older people are more susceptible 
to WNV and TBEV). With ZIKV disease, in addition to the risk for pregnant women, 
men are more often affected by GBS. In TBEV infections, men in older patient groups 
tend to be more at risk of contracting severe encephalitis. In addition, genetic variation 
in several host genes, such as MHC-1 and phospholipase C in DENV infection and DC-
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SIGN, CCR5, TLR3, OAS and TNF-α in TBEV, may influence the severity of the 
disease  (200-204). 
 
 
 
Figure 14. Maximum clade credibility tree of TBEV-Eur isolated in Kuutsalo (arrow), Finland. 
 
The two patients described here had very aggressive and rapid progression of the 
disease. The first patient was young and previously healthy, and she died after three 
days of hospitalization due to herniation. The second patient was immunocompromised, 
and he died after four weeks in the hospital due to tetraplegia and subsequent 
complications. Notably, in both cases, initial antibody titers to TBEV were low. The 
impact of the amino acid substitutions of the Siberian strains on virulence requires 
further investigation, as does potential host susceptibility factors. The coexistence of the 
two TBEV subtypes in the same focus is surprising. Furthermore, two fatal cases 
occurring in a small focus a few weeks apart is uncommon. These findings warrant 
further surveys on the distribution and prevalence of these viruses. 
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Anti-­‐ZIKV	  potential	  of	  obatoclax,	  saliphenylhalamide	  and	  gemcitabine	  (II)	  
As there is no specific antiviral treatment for ZIKV infections, we wanted to screen 
several potential antiviral compounds using the new clinical isolate, the ZIKV FB-
GWUH strain. We investigated six anti-cancer compounds for their efficiency to inhibit 
ZIKV infection: obatoclax, SaliPhe, gemcitabine, SNS-032, dinaciclib and MK2206. 
Obatoclax (GX15-070) is a phase two anti-cancer drug that inhibits Bcl-2 family 
proteins, inducing apoptosis in cancer cells. It has been shown to inhibit the endocytosis 
of several viruses, such as influenza A and B and Sindbis virus by targeting the cellular 
Mcl-1 protein (205). Saliphenylhalamide (SaliPhe) is a vacuolar ATPase (vATPase) 
inhibitor that prevents the acidification of endosomes. SaliPhe is in pre-clinical phase 
for cancer treatment and it has been shown to be effective against influenza viruses and 
papilloma virus by arresting viral entry into endosomes (180,206). Gemcitabine 
(difluorodeoxycytidine) is a pyrimidine analogue that has been used to treat breast, lung 
and pancreatic cancer, for example. Gemcitabine can incorporate into DNA and RNA  
(207). It has also been shown to inhibit replication of the abovementioned viruses (205). 
Compounds that inhibit cyclin-dependent kinases (CDKs) (SNS-032 and dinaciclib) and 
protein kinase B (PLB, also known as Akt) (MK2206) and have an effect on influenza 
A virus infection were also included in this study (195,208). We tested these 
compounds on FB-GWUH-infected retinal pigment epithelial cells, which are also 
involved in ZIKV pathogenesis.  
We found that obatoclax, SaliPhe and gemcitabine were able to inhibit ZIKV 
replication, protein synthesis and infectious virus particle production at non-cytotoxic 
concentrations via the measurement of cell viability, viral RNA production, antigen 
presentation and infectious virus production (Figures 15 and 16). Furthermore, 
inhibition was observed at nanomolar concentrations when the cells were treated with 
different combinations of the compounds. A substantially lower concentration (62 nM 
compared to 1 µM) of SaliPhe together with 62 nM obatoclax was sufficient to inhibit 
ZIKV infection. To evaluate the significance of the combined effect of the given 
compounds, we compared the observed responses to the expected combination 
responses using a zero interaction potency (ZIP) model (209). Although obatoclax-
gemcitabine, obatoclax-SaliPhe and SaliPhe-gemcitabine combinations were classified 
as antagonistic, synergistic interactions were found at multiple doses for these 
combinations. Based on the average synergy scores over the whole landscape, we 
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concluded that a combination of obatoclax-SaliPhe at non-cytotoxic concentrations 
could enhance the inhibition of ZIKV infection. We also investigated the effect of the 
time of addition and the time of treatment on cell viability of infected cells. Obatoclax 
and SaliPhe were able to protect cells from ZIKV-induced cell death when added during 
the first hours of infection, but the effect of gemcitabine was notable even when added 
several hours post-infection.  
 
 
 
Figure 15. Obatoclax, SaliPhe and gemcitabine, but not dinaciclib, SNS-032 or MK2206, inhibit 
ZIKV-induced cell death at µM concentrations. (A) Cells were treated with compounds at increasing 
concentrations in mock and ZIKV-infected cells. The cell viability was measured via CTG assays. (B) 
The effective concentration (EC) 90, EC50, and cytotoxic concentration (CC50) values and the SI indexes 
were calculated. Reproduced with permission from Kuivanen et al. Antiviral Res. 2017. 
 
Traditionally, the antiviral agents target the virus components. Flaviviral enzymatic 
proteins, such as NS3, are well conserved among different species and thus provide a 
solid base for broad-spectrum antiviral agents. In comparison, treating HIV and HCV 
with protease inhibitors have proven effective (210). Polymerase inhibitors are also 
attractive targets for antiviral development as NS5 lacks a eukaryotic homologue. 
Another approach for antiviral screening and development are the cellular targets. 
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Several cellular target candidates for anti-ZIKV and antiflavivirus agents have been 
reported. a-Glucosidase modifies the N-linked glycans and participates in the folding 
and maturation of flaviviral glycoproteins. a-Glucosidase inhibitors have been shown to 
possess broad-spectrum antiviral activity against flaviviruses and many other enveloped 
viruses, but they need to be administered at high dosages and are relatively toxic (30). 
Chloroquine, which is an anti-malarial drug, is shown to inhibit ZIKV infection by 
raising the endosomal pH in cells of neural origin (211). Similar to chloroquine, SaliPhe 
also functions in the early steps of ZIKV infection by inhibiting the endocytosis. Host 
targets have high potential for broad-spectrum antiviral development, which is also a 
prerequisite, since even closely related flaviviruses can use cellular targets differently. 
ZIKV is neurotropic, which directly affects the approach of drug design and discovery. 
Flaviviruses can be in high loads in the brains, which makes the crossing of the BBB a 
crucial pharmacokinetic aspect. In addition, ZIKV infection affects the fetus most 
severely, which makes the antiviral challenge even greater. Many (antiviral) compounds 
are not recommended for use during pregnancy. Recently, a large library of US Food 
and Drug Administration (FDA) -approved drugs was screened for anti-ZIKV activity 
(212). All together 20 compounds showed anti-ZIKV effect, and the nucleoside 
analogue gemcitabine was discovered effective in HUH7 cells, simultaneously to our 
study. Together with previous studies, antiflaviviral activity was shown for bortezomib, 
ivermectin and mycophenolic acid (MPA) by inhibiting virus replication (213-215). 
However, many of these drugs warrant caution of use during pregnancy, gemcitabine 
among them. Obatoclax inhibits a wide range of Bcl-2 proteins that possess pro and 
anti-apoptotic properties. Mcl-1 is an anti-apoptotic protein that has been identified as a 
target for obatoclax. Obatoclax is also reported to reduce the acidity in endosomal 
vesicles, and is thus able to inhibit the entry of ZIKV. Identification of Mcl-1 provides a 
foundation for further anti-ZIKV drug development. Furthermore, there is an indication 
that obatoclax mesylate is able to cross the BBB (216).  
The search for anti-ZIKV drugs has accelerated after the epidemic in the Americas. 
However, the discovery of new antiviral agents is its initials steps towards approved 
treatments for acute ZIKV or flavivirus infections in general. Drugs targeting the 
cellular functions is a promising approach as RNA viruses are prone to mutations. In the 
present study, we found anti-ZIKV compounds that inhibit the endosomal acidification 
and de novo pyrimidine synthesis, and which function in nonocytotoxic concentrations. 
Our data provides a foundation for the further identification of anti-ZIKV compounds 
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and widens the application spectrum of obatoclax, SaliPhe and gemcitabine. These three 
compounds inhibit ZIKV infection in vitro in retinal cells, and the results need to be 
further verified in cells of neural origin as well as in vivo.  
 
 
 
 
 
Figure 16. Obatoclax, SaliPhe and gemcitabine inhibit ZIKV virus replication in RPE cells. (A) 
Mock, ZIKV-infected and compound-treated cells were stained for ZIKV antigens using ZIKV-positive 
patient serum and a FITC-conjugated secondary antibody. (B) RT-qPCR of ZIKV RNA from mock, 
ZIKV-infected and compound-treated cell culture supernatants. (C) ZIKV virus titers were determined 
from ZIKV-infected and compound-treated (2 µM) cell culture supernatants. Reproduced with permission 
from Kuivanen et al. Antiviral Res. 2017. 
 
61  
Obatoclax,	  saliphenylhalamide	  and	  gemcitabine	  differentially	  affect	  cellular	  
signaling,	  transcription	  and	  metabolism	  (II)	  
We further investigated the effect of the three compounds on cellular transcription, 
signaling, metabolism and apoptosis in ZIKV-infected and uninfected cells. Recently, 
Frumence and others showed that ZIKV infection activates caspases 3 and 9 to induce 
apoptosis in lung epithelial A549 cells (217). ZIKV-induced apoptosis has also been 
reported in neural progenitor cells where caspase 3/7 was activated at 24 hpi (218). We 
tested the effect of the compounds on caspase activation. RPE cells were treated with 1 
µM concentrations of the compounds and were then infected with ZIKV. At 40 hpi, 
caspase 1, caspase 3/7, caspase 8 and caspase 9 activities were measured. Obatoclax, 
SaliPhe and gemcitabine were able to block ZIKV-induced apoptosis by inhibiting 
caspase 3/7. Inhibitors of caspases could further broaden the targets for ZIKV antivirals. 
We next tested the effect of these compounds on the transcription and phosphorylation 
statuses of cellular proteins. Using a targeted phosphoprotein-profiling assay, we found 
that at 10 hpi, ZIKV infection and gemcitabine treatment affected the phosphorylation 
status of CREB1, a cyclic AMP-responsive element binding protein. CREB1 is 
involved in cell survival, growth, differentiation and transcriptional regulation of 
antiviral responses (219). All compounds affected the phosphorylation status of CREB1 
in uninfected cells, but only gemcitabine did in ZIKV-infected cells. The 
phosphorylation status of cyclin-dependent kinase (CDK) inhibitor 1B (p27) was 
affected by obatoclax and gemcitabine treatment in ZIKV-infected and uninfected cells. 
In addition to CDK inhibition, p27 regulates the progression of the cell cycle (220). It 
has been suggested suggested that ZIKV reduces cell proliferation and increases 
apoptosis  (218). Using an RNA microarray, we were able to profile cellular target gene 
expression. Obatoclax and SaliPhe inhibited several cellular genes, whereas 
gemcitabine-treated cells also expressed antiviral genes. We further verified these 
results through mRNA detection of IFIT1, IFIT2 and IFIT3 (Figure 17). The three 
compounds differentially affected uninfected cells, and SaliPhe had no effect on cellular 
gene expression (Figure 17).  
We analyzed 110 metabolites in cell culture supernatants from ZIKV infected and 
compound-treated cells at 48 hpi. Reliable quantification was achieved for 92 
metabolites. Surprisingly, the purine metabolite levels were affected by obatoclax and  
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Figure 17. Obatoclax and SaliPhe, but not gemcitabine, deregulated the transcription of antiviral 
genes. (A) Heatmap showing the 96 most variable genes affected by ZIKV infection and the tested 
compounds. (B) RT-PCR analysis of the IFIT1, -2 and -3 genes and ZIKV RNA from infected and 
compound-treated cells. Reproduced with permission from Kuivanen et al. Antiviral Res. 2017. 
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SaliPhe and, to a lesser extent, by gemcitabine. For example, adenosine, guanosine, 
inosine monophosphate (IMP) and adenosine levels were deregulated by the three 
compounds and by ZIKV infection. 
We conclude that gemcitabine inhibits ZIKV replication by interfering with the 
transcription of viral (but not cellular) RNA, whereas obatoclax and SaliPhe target the 
endocytosis of ZIKV. Furthermore, this data provides information on ZIKV-host 
interactions. ZIKV infection did not induce antiviral responses in RPE cells, as seen in 
the transcription profiles: the expression levels of IFNs or IFN-stimulated genes were 
not increased in response to ZIKV infection. In addition, none of the proteins involved 
in antiviral gene expression, such as interferon regulatory factor 3 (IRF3), heat shock 
protein 27 (HSP27), p38 mitogen-activated protein kinase (MAPK), c-Jun N-terminal 
kinases (Jnk), protein kinase B (Akt) and extracellular signal regulated kinases (ERK), 
were shown to be activated in the phosphoprotein-profiling assay, indicating that the 
IFN pathway was not activated in ZIKV-infected RPE cells. To assess the regulation of 
IFN responses upon ZIKV warrant for further functional studies both in vitro and in 
vivo.  
 
ZIKV	  cell	  tropism	  (III)	  
ZIKV has been shown to possess vast tissue tropism and persistence in tissues and body 
fluids, such as urine, saliva and semen (135,136). In addition to three mosquito cell 
lines derived from tissues and organisms important in ZIKV infection, we investigated 
the in vitro cell susceptibility of ten human cell lines originating from the brain, skin, 
kidney, fetal lung, uterus, placenta, and umbilical vein to four ZIKV strains. We 
compared the infectivity of the fetal brain isolate FB-GWUH to two closely related 
strains isolated from serum samples of acute ZIKV cases in French Polynesia in 2013 
(H/PF) and Martinique in 2015 (MRS OPY) as well as to the prototypic strain MR766 
from Uganda in 1947. The three clinical isolates were of low passage: FB-GWUH-2016 
was of passage 0, H/PF was of passage 2 and MRS OPY was of passage 6. The 
prototypic strain MR766 has been passaged numerous times in VeroE6 cells and mouse 
brains, hampering interpretations of the results using this strain as a representative of 
African ZIKV viruses. 
We chose day three post infection as the analysis time point, since we wanted to 
observe the initial replication competence and virus production in these cells. The 
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apparent tropism of ZIKV to neuronal cells has initiated several studies on different cell 
types of the brain. ZIKV preferentially infects neural stem cells, oligodendrocyte 
precursor cells, astrocytes and microglia, whereas neurons are not reported to be as 
readily infected (221). FB-GWUH has also been shown to infect neural progenitor cells, 
causing premature differentiation in human brain organoids (222). In our study, we used 
two cell lines originating from adult human brains, glial cell lines H2 and H4. Both cell 
lines were infected by FB-GWUH and MR766 (>1 log growth), but replication was 
lower for H/PF and MRS OPY (Figure 18). However, infectious virus production was 
more efficient in H/PF-infected H-2 cells compared to those infected with MR766, 
showing similar competence as FB-GWUH (Figure 19). In H4 glioma cells, only FB-
GWUH was able to replicate and produce a notable amount of infectious virus particles. 
H-2 cells were ZIKV-antigen positive for all four strains via IFAs, whereas no antigen 
could be detected by day 3 in H-4 cells. The infection did not induce any antiviral MxA 
measured by mRNA production in either H-2 or H-4 cells (Figure 20). All of the ZIKV 
strains induced a cytopathic effect (CPE) in H2 cells, whereas the replication of only 
FB-GWUH was high enough to induce CPE in H4 cells.  
The uterus (SK-UT-1), newborn microvascular endothelial (HMEC-1) and human 
keratinocyte (HaCaT) cells were more readily infected by FB-GWUH and MR766 than 
by H/PF and MRS OPY, as shown by increases in viral RNA and detectable amounts of 
antigen in the IFAs. However, the infectious virus particle production of FB-GWUH 
was most efficient in SK-UT-1 and HMEC-1 cells. The infection did not induce MxA 
expression in any of these cell lines, despite the efficient production of virus. 
 
 
Figure 18. ZIKV viral RNA load in 10 human and 3 mosquito cell culture supernatants at 0 and 
3 days post-infection. Values presented are log-transformed viral loads from three independent 
experiments. *P-value <0.05 compared to day 0. Reproduced with permission from Kuivanen et al. J Gen 
Virol. 2017. 
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Cell lines from the placenta (JAR), umbilical vein (HUVEC) and adult kidney (A498) 
were susceptible to infection and showed high rates of replication of all four strains (>1 
log, except for MRS OPY in JAR) (Figure 18). CPE was pronounced in these cells as 
virus production was highly effective. Interestingly, the infection induced high MxA 
expression levels only in A498 cells, whereas in JAR or HUVEC cells, MxA mRNA 
was not detected (Figure 20). The cell lines and tissue sections from the female 
reproductive system have previously been shown to be highly permissive for ZIKV. El 
Costa and others have shown in an ex vivo transplant model that the maternal decidua, 
placenta and umbilical cord are permissive to ZIKV infection (169). Placenta origin 
cells and endometrial stromal cells have been shown to be important for virus 
persistence and dissemination (168). Placental macrophages, or Hofbauer cells, are 
highly susceptible to ZIKV, but trophoblasts are to a lesser extent, which further 
addresses the higher risk of infection during the first trimester of pregnancy  (170). 
 
 
Figure 19. Infectivity of ZIKV in 10 human cell lines at 3 dpi. *P-value <0.05 compared to FB-
GWUH. Reproduced with permission from Kuivanen et al. J Gen Virol. 2017 
 
Newborn foreskin epithelial (HFSF) and fetal lung (MRC-5) fibroblasts were infected 
(>1 log replication) by all viruses (except for the slightly lower replication of MRS 
OPY in HFSF) (Figure 18). Fibroblasts are one of the foundational cell types shown to 
be infected by ZIKV (169). Fetal MRC-5 fibroblasts showed a higher rate of ZIKV 
antigen positivity via IFAs than newborn HFSF fibroblasts. ZIKV infection did not 
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induce a cytopathic effect in either of the HFSF or MRC-5 cell lines, but a productive 
infection was still established. Unlike most of cell lines studied here, infection induced 
MxA expression in both HFSF and MRC-5 cells. The MxA expression levels were 
higher in FB-GWUH and H/PF infected cells, in accordance to infectious virus 
production (Figure 20).  
In this study, we also tested three mosquito cell lines for their susceptibility to ZIKV 
infection. We used cell lines representative of the main vector for ZIKV, Aedes aegypti 
(AE), as well as cell lines from Aedes pseudocutellaris (AP61) and Aedes alpobictus 
(C6/36), the latter of which is commonly used for the isolation of mosquito-borne 
flaviviruses. Somewhat surprisingly, using the same infection conditions as with the 
human cell lines, these mosquito cells showed no or little replication of any of the 
strains at day 3 post-infection (Figure 17). Therefore, the experiment was repeated with 
a higher MOI (0.2) and longer time scale (0, 5 and 12 days). Efficient replication (>1 
log) was observed in the iRNA deficient C6/36 cells, whereas only modest growth was 
observed in the other two cell lines (our unpublished results). The isolation trial from 
the fetal and maternal tissues (I) was also unsuccessful when attempted directly in 
C6/36 cells.  
 
 
Figure 20. Induction of MxA mRNA production at 3 dpi. The fold change between ZIKV-infected and 
mock-infected cells is shown. Reproduced with permission from Kuivanen et al. J Gen Virol. 2017. 
 
To obtain a general overview of innate immune activation in the human cell lines used 
in the study, we measured the relative induction of MxA mRNA in the infected cells. 
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Interestingly, ZIKV infection induced MxA mRNA in only three of the 10 cell lines, 
fibroblasts, HFSF and MRC-5, and in A498 adult kidney epithelial cells. Flaviviruses 
have evolved strategies to circumvent or inhibit innate immune responses in the host or 
to mask antigen presentation to avoid immune responses (62,82). Many of the non-
structural proteins, as well as sub-genomic flavivirus RNA (sfRNA), have been shown 
to function in antagonizing the initial innate immune responses. ZIKV NS5 induces 
proteasomal degradation of STAT2, and sfRNA of ZIKV inhibits signaling down-
stream of RIG-I/MDA5 (75). The failed induction of MxA in the studied cell lines 
remains merely an observation, and the underlying reason can only be speculated.  
Our study highlights the differences in biological properties of the three epidemic ZIKV 
strains. The fetal brain-derived FB-GWUH strain was able to replicate and produce a 
productive infection in all of the ten human cell lines tested. We found differences in 
cell susceptibility particularly in cell lines originating from the placenta, umbilical 
veins, kidney and brain that favored the new strain and a closely related French 
Polynesian strain. Key aspects in ZIKV pathogenesis is the production of productive 
infection without cytopathology. In our study, ZIKV induced cytopathic effect in most 
of the cell lines, except for fibroblasts. ZIKV has been shown to be able to produce 
persistent infection in primary human brain microvascular endothelial cells as well as in 
prostatic, testicular and renal cell lines without inducing CPE (171,223).  
FB-GWUH has 10 and 13 amino acid differences compared to the epidemic H/PF and 
MRS OPY strains, respectively. Nine of the amino acid substitutions are specific for 
FB-GWUH, which suggests that one or more of the amino acid differences between the 
epidemic strains is responsible for the differences in their replication efficiency. MRS 
OPY and H/PF are more closely related to each other, having only 5 amino acid 
differences. The amino acid substitutions between the epidemic strains and the 
prototypic MR766 strain are too numerous to allow any profound conclusions on their 
differences. However, one of the mutations between FB-GWUH and MRS OPY and 
H/PF is a convergent mutation towards the African lineage. Both MR766 and FB-
GWUH have a threonine in site 2679 (NS5). The impact of these amino acid 
substitutions requires further studies. 
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CONCLUDING	  REMARKS	  
In a constantly changing world, viruses evolve and adapt to prevailing circumstances. 
Members of the Flavivirus genus are of arthropod-borne RNA-viruses that have the 
ability to evolve and spread rapidly along with their vector hosts. The focus of this 
thesis work was two neuropathogenic flaviviruses, Zika virus and tick-borne 
encephalitis virus, viruses that have emerged during the last few years. 
Zika virus has caused an alarming epidemic in the Americas in 2015-2016. In the 
beginning of the epidemic, new disease manifestations were connected to ZIKV 
infections: CNS complications including microcephaly and Guillain-Barré syndrome. 
These suspected disease associations were new, and a large number of studies were 
warranted to uncover the epidemiological and virological characteristics of the disease 
and to prove the causal link between the pathogen and the disease. We were able to 
provide key evidence of causality by isolating ZIKV from an affected fetal brain. We 
described for the first time a case of prolonged maternal viremia weeks after ZIKV 
infection during pregnancy, suggesting infection and active ZIKV replication in the 
fetoplacental system, and we subsequently isolated the pathogen, ZIKV FB-GWUH-
2016. 
We studied the effect of known anti-cancer and potent antiviral compounds to ZIKV 
FB-GWUH infection. We found that novel compounds obatoclax and 
saliphenylhalamide, as well as the previously known gemcitabine, inhibit ZIKV-
mediated cell death in retinal epithelial cells. These results provide a foundation for the 
future identification of antiviral agents and further broaden the spectrum of activities of 
these three compounds. We further elaborated cell-virus interactions during ZIKV 
infection using these compounds. 
We characterized the new ZIKV isolate in vitro by investigating its potential to infect 
human cell lines. Furthermore, we compared FB-GWUH to two other related epidemic 
strains of Asian lineage isolated from the sera of adult febrile patients in French 
Polynesia and Martinique. We also included the prototypic strain MR766 from the 
African lineage in our comparison. We found that cell lines from the placenta, umbilical 
veins, kidney and brain favor FB-GWUH replication. 
We also described two fatal cases of tick-borne encephalitis virus in a new focus in 
Finland, as well as the subsequent isolation of TBEV-Sib from a brain using the same 
human neuroblastoma cell line that was used for ZIKV isolation. We found that both 
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the European and Siberian subtypes of the virus circulate in the same focus. Fatal 
TBEV infections are rare, and two cases reported temporally and geographically close 
to each other are uncommon. The emergence of more pathogenic variants of TBEV 
requires further surveys on their spread and studies on their virulence.  
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